Anne-Lise Børresen-Dale
- Professor emerita; PhD, MD (h.c.)
- +47 22 78 13 73
Born 030746, Molde, Norway
Addresses:
1. Department of Genetics, Institute for Cancer Research, Oslo University Hospital The Norwegian Radiumhospital.
2. Institute for Clinical Medicine, Faculty of Medicine University of Oslo, Norway.
Phone: +4722781373, Fax: +4722781395 Cell phone: +4792854455
Email: a.l.borresen-dale@medisin.uio.no
Anne-Lise Børresen-Dale is Professor Emerita at University of Oslo and previous head of Department of Cancer Genetics, Oslo University Hospital Radiumhospitalet. She is among the leading geneticists in research on molecular biology of breast cancer, and her group was among the pioneers in expression profiling of breast carcinomas in collaboration with groups at Stanford, demonstrating that breast cancer can be divided into distinct sub-groups with differences in molecular profiles and in overall and relapse-free survival. Her achievements are seminal for understanding breast cancer evolution, and have had an enormous impact on our view of the complexity of breast cancer. She is author of more than 500 published scientific papers, books chapters and invited reviews.
Børresen-Dale was director of the K.G. Jebsen Center for Breast Cancer Research with a major funding from the K.G. Jebsen Foundation in the period 2011-2016. (http://stiftkgj.no/hva-vi-gjor/k-g-jebsen-medisinske-sentre/k-g-jebsen-senter-for-brystkreftforskning/)
Børresen-Dale has received several prizes and awards, some of the most prestigious being the Swiss Bridge Award for Outstanding Cancer Research in 2004, the Möbius prize for outstanding Research from the Research Council of Norway in 2008, The Mildred Scheel Lecturership in 2015, the Fritjof Nansen medal and award for Outstanding Research from the Academy of Science and Letters, Norway in 2015, the AACR Distinguished Lectureship in Breast Cancer Research in 2015 and the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship and award in 2017. She was appointed to Commander of the Royal Norwegian St. Olavs Order by the King of Norway in 2017. Børresen-Dale has been Member of the Board of Directors of both AACR and ECCO, is past president of EACR, and is Elected Member of The Royal Academy of Science, Norway, The Norwegian Academy of Science and Letters and the European Academy of Cancer Sciences.
Børresen-Dale's research has been focusing on Exploring the Systems Biology of Breast Cancer using high dimensional data in integrated approaches aiming at identification of genotypes and gene expression profiles contributing to elevated cancer risk, radiation sensitivity, tumor aggressiveness and therapy resistance. The goal has been to follow the linear time course of predisposition, initiation, early stages and advanced disease and to dissect the molecular mechanisms triggered at each stage and to follow the multidimensional interactions at various levels in a systems biology approach to be able to better do risk estimation, prognostication and prediction.
Ongoing external activities:
- Member of External Advisory Group of the EU7FP project REQUITE: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors. https://www.requite.eu/
- Scientific Advisory Board member of the Center of Molecular Medicine, Umeå University, Sweden. http://www.ucmm.umu.se/english/
- Scientific Advisory Board member, German Consortium for Translational Cancer Research (DKTK). https://dktk.dkfz.de/en/home
- Scientific Council member, Deutsches Krebsforschungszentrum (DKZF) Heidelberg, Germany. https://www.dkfz.de/en/index.html
- Scientific Advisory Board member of the cancer genomics research program CIT (Tumor Identity Cards) of the French League Against Cancer.http://cit.ligue-cancer.net
- Academic committee member, Aker Scholarship. http://www.akerscholarship.no/akademisk-komite/
- Scientific Advisory Board member of SAGA Diagnostics. http://sagadiagnostics.com/
- Member of the Board of Arctic Pharma. http://www.arcticpharma.com/
- Member of the nomination committee, Oslo Cancer Cluster OCC http://oslocancercluster.no/
- Chairman of Sigurd K Thoresens Legacy. http://www.thoresenslegat.no/
- Scientific Advisory Board member of the EU2020 project MESI-STRAT: Systems Medicine of Metabolic-Signaling Networks (Breast cancer metabolism- a new concept for patient stratification). https://mesi-strat.eu/
- Member of the FEBS/EMBO Women in Science Award committee. http://www.embo.org/funding-awards/women-in-science-award
Academic Degrees.
1970 M.Sc. Biochemistry, Technical University of Norway, Trondheim, Norway.
1978 Doctor of Science in Medical Biochemical Genetics, University of Oslo, Norway.
1987 Judged qualified as a professor in gene technology, University of Oslo, Norway.
1992 Professor in Molecular Tumor biology, Univ. of Oslo, Norway (still holding)
Main Positions held
1970-72 Research assistant, Institute of Medical Genetics, University of Oslo.
1972-78 Research Fellow, Institute of Medical Genetics, University of Oslo.
1978-82 Senior Research Fellow, Institute of Medical Genetics, University of Oslo
1982-86 Senior Biochemist, Head, section for prenatal diagnosis, Department of Medical Genetics, UiO
1987-99 Senior Scientist, Dept. of Genetics, Inst. for Cancer Research, DNR, Norway
1999-present Head of Department, Dept. Genetics, Inst. for Cancer Research, OUS/DNR, Norway
Honors and awards
1989 Prof.Olav Torgersens Prize and Memorial Lecture: Gene tech. in the fight against cancer.
1989 Honorary lecturer at the 175th anniversary of the Medical Faculty, Univ.Oslo.
1994 King Olav V's Cancer Research Prize
1998 Member of The Royal Academy of Science, Norway
2001 Honorary member of The Norwegian Biochemical Society
2002 University of Oslo's Research Prize for Outstanding Research
2002 SalusAnsvar Medical prize for Outstanding Research in Tumor biology
2002 The Employer of the year at The Norwegian Raduimhospital
2004 Member of The Norwegian Academy of Science and Letters
2004 Swiss Bridge Award for outstanding Cancer Research
2008 Doctor medicinae honoris causa, University of Copenhagen
2008 The Möbius prize for outstanding Research from The Research Council of Norway
2009 ESTRO Honorary member award
2009 International Journal of Cancer/ Meyenburg-Stiftung Joint Lectureship distinguished speaker
2009 Elected member of the European Academy of Cancer Sciences
2009 Associate Investigator of Centre for Molecular medicine (NCMM), Nordic EMBL Partnership
2010 Honorary ambassador of the Norwegian Cancer Society
2012 Honorary member of The Hungarian Cancer Societ
Research work abroad (3-6 months)
1972: Dep. Hum.Biol.Chem& Gen, Univ. Texas, (Barbara Bowman), protein sequencing.
1977: The Rockefeller University, New York (Thomas Kindt), protein sequencing
1985: EMBL (Hans Lerach), recombinant DNA‑techniques
1986: Recombinant DNA Tech. Lab, Helsinki, Finland (Leena Peltonen,)
1990: Harvard Med. Sch., Mass. (David Yandell), PCR/SSCP on Rb,
1992: MIT, Cent. Envir. Health Sci. MA (William Thilly), mutation assay systems
1992: MGH Cancer Cent and Harvard Med. Sch, Boston, MA (Stephen Friend)
2002: Visiting Prof, Dept of Genetics, Stanford Univ.CA (David Botstein), Microarray analyses.
Teaching responsibilities
Supervised: 40 PhD stud (22 as main supervisor, 5 ongoing, 3 as main), 18 MSc stud. (10 as main superv)
PBL Medical Students since 96.
Selective Administrative Experience on national and international Boards
1986-91: Secretary General, The Norwegian Biochemical Society.
1989-1993: PI of a Nordic technology development project financed by Nordisk Industrifond
1995-00: Chair of expert committee on Biotech. and Genetics. Norwegian Board of Health.
1995-00: Chairman of the program committee, MedKap, NFR
1999-02: Member of the Scientific Council, International .Agency for Res. of Cancer, IARC, Lyon
2002-03: Vice-Chairman of the Scientific Council, IACR, Lyon
2001-04: Board member of the National Committee for Functional Genomics, FUGE
2003-06: Member of The Board of Directors, American Ass. for Cancer Res. (AACR)
1996-06 Member of The Scientific Board "Forskningutvalget" DNR/RR-HF.
2004-08 One of the PI's in the EU Integrated project on "Mutant TP53 and Cancer"
2000 Member of the Scientific Committees for the 2nd ESF conference, and ECCO 13
2006- 08 President Elect, European Association for Cancer Research, EACR
2007- Scientific Advisory Board, CREATE HEALTH Consortium Lund Sweden
2008-10 President EACR
2008-12 Board of Directors and Executive committee as Treasure, ECCO (European CanCer Organization)
2008-10 Member of the Nomination Committee, AACR
2008- External Advisory Board (EAB) of the SPORE in Breast Cancer at Univ. of North Carolina
2010-13 Scientific Advisory Board member, DKZF, Heidelberg, Germany'
2011-13 Council of Scientific Advisors, AACR (American Association for Cancer Research)
2011 Scientific co-chair, ECCO16 Conference, Stockholm
2011- Senior Associated Editor, Molecular Oncology
2011-16 Director of the K.G.Jebsen Centre for Breast Cancer Research
2011-14 Chair of Scientific Advisory Board for TRANSCAN ERA-net
2012 Chair and organizer of International Symposium on Personalized Cancer Care
2013- Scientific Board of the Pezcoller Foundation
2013-16 Scientific Advisory Board, German Consortium for Translational Cancer Research (DKTK)
2013 Basic Science track chair, ECCO17 Conference, Amsterdam
2013-18 External Advisory Group, ReQuiTe: Radiotherapy for Quality of life through reduced Toxicity
2014-15 Breast Cancer track chair, ECCO18 Conference, Vienna
Publications:
Author of 438 published/in press scientific papers, 40 chapters in books and invited reviews, 33 articles in Nordic journals and books
Main funding
1) Annually from the Cancer Society of Norway, on Exploring the Systems Biology of Breast Cancer.
Pt: One postdoc (50%, ending march 2015) one postdoc 100% ( to start August 2014), 2 technicians and laboratory expenses
2) 2011-2015: Funding for a K.G Jebsen Center for Breast Cancer Research
3) 2013-2017: Funding from HSØ for a PhD student and a post doc in the project : Exploring the Systems Biology of Breast Cancer, focusing on noncoding RNA and its role in breast cancer progression
4) 2012-2015: NFR grant together with GM Mælansdmo, MetAction: Actionable Targets in Cancer Metastasis - from Bed to Bench to Byte to Bedside
5) EU-7FP: BASIS: Breast Cancer Somatic Genetics Study under HEALTH-2009-2.1.1-2: Large-scale functional genomics efforts to identify molecular determinants of cancer:
6) EU-7FP: "GlycoHIT: Glycomics by High-throughput Integrated Technologies: Development and validation of complementary and integrated technologies for glycomic analysis of serum in cancer glycobiomarker discovery, diagnostics and glycotherapeutic monitoring" under HEALTH 2010.1.1-3: High-throughput analysis of posttranslational modifications of proteins.
7) EU-7FP: "EUROCANPLATFORM" A European Platform for Translational Cancer Research: Network of Excellence under HEALTH 2.4.1-2 .
Selected peer-reviewed publications (from a total of 458)
Citations(>10) per May 28. 2014 marked in blue
1. Perou, CM., Sørlie, T., Eisen, MB., van de Rijn, M., Jeffrey, S. S., Pollack, JR., Rees, CA., Ross, DT., Johnsen, H., Akslen, LA., Pergamenschikov, CW., Zhu, SX., Lønning, PE., Børresen-Dale, AL., Brown, PO. and Botstein, D.: Molecular portraits of human breast tumours. Nature 406: 747-52, 2000. 7724 citations
2. Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Hastie, T., Johnsen, H., Eisen, M.B., Thorsen, T., Rijn, M. van der., Jeffrey, S., Quist, H., Rees, C. A., Brown, P.O., Botstein, D., Lønning, P.E. and Børresen-Dale, A.-L.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with potential clinical implications. PNAS 98 (19): 10869-74, 2001. 5980 citations
3. Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., Perou, C. M., Lønning, P. E., Brown, P. O., Børresen-Dale, A.-L., and Botstein, D.: Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS., 100 (14): 8418-8423, 2003. 3387 citations
4. Hicks, J., Krasnitz, A., et al and Børresen-Dale, A.-L., Naume, B., Schlicting, E., Norton, L., Hagerstrøm,T., Skoog,L., Auer, G,. Måner, S., Lundin, P. and Zetterberg, A.: Novel patterns of genome rearrangements and their association with survival in breast cancer. Genome Res. 16(12):1465-79, 2006. 209 citations
5. Horlings H.M., Bergamaschi A., Nordgard, S H., Kim Y H., Han W., Noh DY., Salary, K., Joosse, S. A., Reyal, F., Lingjaerde, O. C., Kristensen V.N., Børresen-Dale A-L., Pollack J.R. and van de Vijver M.J.: ESR1 gene amplification in breast cancer: a common phenomenon? Letter to editor of Nature Genetics on the publication of Frederik Holst et al. in Nature Genetics 39, 655 - 660 (2007), Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics 40(7): 807-808, 2008. 85 citations
6. Stephens, P. J., McBride, D. J., et al and, Børresen-Dale, A.-L., Campbell, P. J., Futreal, P. A. and Stratton, M. R.: Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature, 462(7276):1005-10, 2009. 450 citations
7. Russnes, H. G., Vollan, H. K. M., Lingjærde, O. C., Krasnitz, A., Lundin, P., Naume, B., Sørlie, T., Borgen, E., Rye, I. H., Langerød, A., Chin, S-F., Teschendorff, A. E., Stephens, P. J., Månèr, S., Schlichting, E., Baumbusch, L. O., Kåresen, R., Stratton, M. P., Wigler, M., Caldas, C., Zetterberg, A., Hicks, J. and Børresen-Dale, A.-L.: Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Science Translation Medicine, 2, 38ra47 (2010) 78 citations
8. Van Loo, P., Nordgard, S. H., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J., Marynen, P., Zetterberg, A., Naume, B., Perou, C. M., Børresen-Dale, A.-L. and Kristensen, V. N.: Allele specific copy number analysis in tumors (ASCAT). 2010. PNAS 107 (39) 16910-16915 Sep.28, 2010, www.pnas.org/cgi/doi/10.1073/pnas.100984310 118 citations
9. Potapenko, I. O., Haakensen, V. D., Lüders, T., Helland, Å., Bukholm, I. R., Sørlie, T., Kristensen, V.N., Lingjærde, O. C. and Børresen-Dale, A.-L.: Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. 2009. Molecular Oncol. 4(2):98-118, 2010. 39 citations
10. Hennessy, B. T., Lu, Y., Gonzalez-Angulo, A.M., Carey , M. S., Myhre, S., Ju, Z., Davies, M. A., Liu, W., Coombes, K., Meric-Bernstam, F., Bedrosian, I., McGahren, M., Agarwal, M., Zhang, F., Overgaard, J., Alsner, J., Neve, R. M., Kuo, W.-L., Gray, J. W. , Borresen-Dale, A.-L. and Mills, G. B.: A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin.Proteom 6:129-151, 2010. 54 citations
11. Enerly, E., Steinfeld, I., Kleivi, G. K., Leivonen, S. K., Aure, M. R., Russnes, H. G., Rønneberg, J. O., Johnsen, H., Navon, R., Rødland, E., Mäkalä, R., Naume, B., Perälä, M., Kallioniemi, O., Kristensen, V. N., Yakhini, Z. and Børresen-Dale, A.-L.: miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. Plos One, 2011 Feb 22:6 (2) e16915 100 citations
12. Edgren H, Murumägi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Wolf M,Børresen-Dale, A.-L. and Kallioniemi O.: Identification of fusion genes in breast cancer by paired- end RNA-sequencing. Genome Biology, 2011 jan.19:12(1):R6. 72 citation
13. Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale, A.-L., and Lindgjærde OC.: Combining gene signatures improves prediction of breast cancer survival. PLoS One, 2011 Mar.10;6(3) e17845. 22 citation
14. Russnes HG, Navin N, Hicks J, Borresen-Dale A.-L.: Insight into the Heterogeneity of Breast Cancer through Next-Generation Sequencing. JCI, Oct 3; 121(10) 3810-8, 2011 70 citation
15. Kristensen, V.N., Vaske, C et al and Børresen-Dale, A.-L.: Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. PNAS Sep 9, 2011 42 citations
16. Curtis C., Shah S.P., Chin S.-F. et al and Børresen-Dale, Brenton J.D., Tavare´S., Caldas C. & Aparicio S.: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486 (7403), 346-52, 2012. 484 citations
17. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Børresen-Dale A.-L., Levine AJ, Bargonetti J and Prives C. Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell.;148(1-2):244-58, 2012. 99 citations
18. Stephens, P.J., Tarpe P et al and, Børresen- Dale,A.-L., Richardson,A.L., Campbell,P.J., P Andrew Futreal,P.A. and Stratton,M.R. The landscape of cancer genes and mutational processes in breast cancer. Nature 486 (7403), 400-4, 2012. 325 citations
19. Nik-Zainal S, van Loo P, Wedge DC et al and Børresen-Dale A.-L, Futreal PA, Stratton MR and Campbell PJ: The Life History of 21 Breast Cancers. Cell, 149 (5), 994-100, 2012. 242 citations
20. A. Margolin, E. Bilal, E. Huang, T. C. Norman, L. Ottestad, et al and The Sage DREAM Breast Cancer Challenge Consortium, V. N. Kristensen, J. Hellerstein, S. Friend, G. Stolovitzky, S.Aparicio, C. Caldas, A.L. Børresen-Dale Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer 2013 Science Translational Medicine, 17 April 2013 Vol 5 Issue 181 181re1.
21. Aure, M. R., Steinfeld, I., Baumbusch, L.O., Lilestøl, K., Lipson, D., Nyberg, S., Naume, B., Sahlberg, K. K., Kristensen, V. N., Børresen-Dale, A.-L., Lingjærde, O.C. and Yakhini, S.: Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data. PlosOne, 2013(8)1e53014
22. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio S, Behjati S,. Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A.-L... Pfister SM, Campbell PJ, and Stratton MR: Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14. 128 citations
23. Engebraaten, Vollan, H.K.M., and Børresen-Dale, A.L.:Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol. 2013 Aug 3. piiS0002-9440(13)00461-6. doi: 10.1016/j.ajpath.2013.05.033
24. Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnæs GI, Perälä M, Busato F, Touleimat N, Tost J, Børresen-Dale AL, Hautaniemi S, Troyanskaya OG, Lingjærde OC, Sahlberg KK, Kristensen VN Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biol, 14 (11), R126 PubMed 24257477
25. Vessela N. Kristensen, Ole Christian Lingjærde, Hege G. Russnes, Hans Kristian M. Vollan, Arnoldo Frigessi, and Anne-Lise Børresen-Dale: Principles and methods of integrative genomic analyses in cancer, Nature Cancer Reviews, VOLUME 14 | MAY 2014 | 303
Publications 2024
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
Mol Oncol, 18 (8), 2042-2059
DOI 10.1002/1878-0261.13656, PubMed 38671580
Publications 2023
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
Cancer Res Commun, 3 (2), 235-244
DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142
Publications 2022
Common variants in breast cancer risk loci predispose to distinct tumor subtypes
Breast Cancer Res, 24 (1), 2
DOI 10.1186/s13058-021-01484-x, PubMed 34983606
Cis-regulatory mutations associate with transcriptional and post-transcriptional deregulation of gene regulatory programs in cancers
Nucleic Acids Res, 50 (21), 12131-12148
DOI 10.1093/nar/gkac1143, PubMed 36477895
Publications 2021
Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer
Genome Med, 13 (1), 72
DOI 10.1186/s13073-021-00880-4, PubMed 33926515
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women
N Engl J Med, 384 (5), 428-439
DOI 10.1056/NEJMoa1913948, PubMed 33471991
Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation
Proc Natl Acad Sci U S A, 118 (45)
DOI 10.1073/pnas.2100050118, PubMed 34737229
Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression
NPJ Breast Cancer, 7 (1), 118
DOI 10.1038/s41523-021-00329-2, PubMed 34508103
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235
Publications 2020
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
Nat Commun, 11 (1), 312
DOI 10.1038/s41467-019-14100-6, PubMed 31949161
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909
Publications 2019
Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation
Nat Commun, 10 (1), 1749
DOI 10.1038/s41467-019-09828-0, PubMed 30988298
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 10 (1), 525
DOI 10.1038/s41467-019-08512-7, PubMed 30692535
Genome-wide association study of germline variants and breast cancer-specific mortality
Br J Cancer, 120 (6), 647-657
DOI 10.1038/s41416-019-0393-x, PubMed 30787463
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201
miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
Microrna, 8 (2), 155-165
DOI 10.2174/2211536608666181206124922, PubMed 30520388
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
J Natl Cancer Inst, 111 (11), 1202-1215
DOI 10.1093/jnci/djz051, PubMed 30990221
Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nature, 566 (7742), E1
DOI 10.1038/s41586-019-0883-2, PubMed 30659290
PathTracer: High-sensitivity detection of differential pathway activity in tumours
Sci Rep, 9 (1), 16332
DOI 10.1038/s41598-019-52529-3, PubMed 31704995
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
The circular RNome of primary breast cancer
Genome Res, 29 (3), 356-366
DOI 10.1101/gr.238121.118, PubMed 30692147
Publications 2018
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 9 (1), 5397
DOI 10.1038/s41467-018-07842-2, PubMed 30559362
Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation
Nat Commun, 9, 16193
DOI 10.1038/ncomms16193, PubMed 29633761
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Genome Med, 10 (1), 92
DOI 10.1186/s13073-018-0601-y, PubMed 30497530
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
Oncoimmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
Oncoimmunology, 7 (11), e1457598
DOI 10.1080/2162402X.2018.1457598, PubMed 30377556
Correction to: A systematic comparison of copy number alterations in four types of female cancer
BMC Cancer, 18 (1), 80
DOI 10.1186/s12885-017-3766-7, PubMed 29338700
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Am J Hum Genet, 104 (1), 21-34
DOI 10.1016/j.ajhg.2018.11.002, PubMed 30554720
Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
Mol Oncol, 12 (9), 1540-1558
DOI 10.1002/1878-0261.12319, PubMed 29741811
Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
Mol Oncol, 12 (11), 1838-1855
DOI 10.1002/1878-0261.12375, PubMed 30133130
N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
Mol Oncol, 12 (6), 972-990
DOI 10.1002/1878-0261.12312, PubMed 29698574
Publications 2017
AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Mol Cancer Ther, 17 (1), 254-263
DOI 10.1158/1535-7163.MCT-16-0868, PubMed 29054988
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
Breast Cancer Res, 19 (1), 44
DOI 10.1186/s13058-017-0812-y, PubMed 28356166
Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma
Sci Rep, 7 (1), 5568
DOI 10.1038/s41598-017-05537-0, PubMed 28717182
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 8 (1), 1221
DOI 10.1038/s41467-017-01355-0, PubMed 29089486
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
Oncotarget, 8 (34), 57121-57133
DOI 10.18632/oncotarget.19078, PubMed 28915659
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Nat Med, 23 (4), 517-525
DOI 10.1038/nm.4292, PubMed 28288110
Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
Cancer Res, 77 (18), 4755-4762
DOI 10.1158/0008-5472.CAN-17-1083, PubMed 28904067
Interactions between the tumor and the blood systemic response of breast cancer patients
PLoS Comput Biol, 13 (9), e1005680
DOI 10.1371/journal.pcbi.1005680, PubMed 28957325
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
Metabolomics, 13 (4), 37
DOI 10.1007/s11306-017-1168-0
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
Oncotarget, 8 (1), 1074-1082
DOI 10.18632/oncotarget.13718, PubMed 27911866
DNA methylation at enhancers identifies distinct breast cancer lineages
Nat Commun, 8 (1), 1379
DOI 10.1038/s41467-017-00510-x, PubMed 29123100
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
Nat Genet, 49 (3), 341-348
DOI 10.1038/ng.3771, PubMed 28112740
Corrigendum: A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
Nat Genet, 49 (11), 1661
DOI 10.1038/ng1117-1661a, PubMed 29074948
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
Nature, 543 (7647), 714-718
DOI 10.1038/nature21703, PubMed 28329761
Association analysis identifies 65 new breast cancer risk loci
Nature, 551 (7678), 92-94
DOI 10.1038/nature24284, PubMed 29059683
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Nat Genet, 49 (12), 1767-1778
DOI 10.1038/ng.3785, PubMed 29058716
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue
Oncoimmunology, 6 (11), e1356142
DOI 10.1080/2162402X.2017.1356142, PubMed 29147603
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters
Am J Pathol, 187 (10), 2152-2162
DOI 10.1016/j.ajpath.2017.04.022, PubMed 28733194
Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
Mol Oncol, 11 (10), 1361-1379
DOI 10.1002/1878-0261.12105, PubMed 28657165
BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer
Cancer Res, 77 (11), 2789-2799
DOI 10.1158/0008-5472.CAN-16-2568, PubMed 28283652
TP53 Mutations in Breast and Ovarian Cancer
Cold Spring Harb Perspect Med, 7 (1)
DOI 10.1101/cshperspect.a026252, PubMed 27815305
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
Oncotarget, 8 (44), 76290-76304
DOI 10.18632/oncotarget.19350, PubMed 29100312
Publications 2016
Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing
Genome Biol, 17 (1), 250
DOI 10.1186/s13059-016-1109-7, PubMed 27931250
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
Nat Genet, 48 (4), 374-86
DOI 10.1038/ng.3521, PubMed 26928228
Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
Oncoimmunology, 5 (12), e1248015
DOI 10.1080/2162402X.2016.1248015, PubMed 28123884
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation
Am J Hum Genet, 99 (4), 903-911
DOI 10.1016/j.ajhg.2016.07.017, PubMed 27640304
Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent
PLoS Med, 13 (8), e1002105
DOI 10.1371/journal.pmed.1002105, PubMed 27551723
Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
Mol Oncol, 11 (2), 220-234
DOI 10.1002/1878-0261.12025, PubMed 28145100
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Front Genet, 7, 85
DOI 10.3389/fgene.2016.00085, PubMed 27242894
Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21
Oncotarget, 7 (49), 80140-80163
DOI 10.18632/oncotarget.12818, PubMed 27792995
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
Cancer Metab, 4, 12
DOI 10.1186/s40170-016-0152-x, PubMed 27350877
Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus
PLoS One, 11 (8), e0160316
DOI 10.1371/journal.pone.0160316, PubMed 27556229
Subtype-specific micro-RNA expression signatures in breast cancer progression
Int J Cancer, 139 (5), 1117-28
DOI 10.1002/ijc.30142, PubMed 27082076
Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells
Genome Res, 26 (5), 717.2
DOI 10.1101/gr.206557.116, PubMed 27197245
A systematic comparison of copy number alterations in four types of female cancer
BMC Cancer, 16 (1), 913
DOI 10.1186/s12885-016-2899-4, PubMed 27876019
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
Nat Commun, 7, 12675
DOI 10.1038/ncomms12675, PubMed 27601076
Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer
Cell Rep, 16 (4), 1166-1179
DOI 10.1016/j.celrep.2016.06.051, PubMed 27396337
The topography of mutational processes in breast cancer genomes
Nat Commun, 7, 11383
DOI 10.1038/ncomms11383, PubMed 27136393
Genetic modifiers of CHEK2*1100delC-associated breast cancer risk
Genet Med, 19 (5), 599-603
DOI 10.1038/gim.2016.147, PubMed 27711073
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nature, 534 (7605), 47-54
DOI 10.1038/nature17676, PubMed 27135926
Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary
Fam Cancer, 15 (1), 85-97
DOI 10.1007/s10689-015-9845-5, PubMed 26446593
RAD51B in Familial Breast Cancer
PLoS One, 11 (5), e0153788
DOI 10.1371/journal.pone.0153788, PubMed 27149063
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Nat Commun, 7, 11479
DOI 10.1038/ncomms11479, PubMed 27161491
Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
Nat Commun, 7, 11908
DOI 10.1038/ncomms11908, PubMed 27264733
Genetic predisposition to ductal carcinoma in situ of the breast
Breast Cancer Res, 18 (1), 22
DOI 10.1186/s13058-016-0675-7, PubMed 26884359
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
J Transl Med, 14 (1), 295
DOI 10.1186/s12967-016-1059-6, PubMed 27756323
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
Cancer Res, 76 (17), 5092-102
DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532
LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer
EMBO Mol Med, 8 (9), 1052-64
DOI 10.15252/emmm.201606198, PubMed 27485121
Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer
Int J Cancer, 139 (6), 1303-1317
DOI 10.1002/ijc.30150, PubMed 27087578
Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer
Cell Rep, 16 (7), 2032-46
DOI 10.1016/j.celrep.2016.07.028, PubMed 27498871
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration
Nat Commun, 7, 12910
DOI 10.1038/ncomms12910, PubMed 27666519
Determinants of acquired activated protein C resistance and D-dimer in breast cancer
Thromb Res, 145, 78-83
DOI 10.1016/j.thromres.2016.08.003, PubMed 27505249
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus
Breast Cancer Res, 18 (1), 64
DOI 10.1186/s13058-016-0718-0, PubMed 27459855
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry
Cancer Causes Control, 27 (5), 679-93
DOI 10.1007/s10552-016-0741-6, PubMed 27053251
Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy
Biomed Hub, 1 (3), 1-9
DOI 10.1159/000453253, PubMed 31988890
Publications 2015
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
Genome Med, 7 (1), 21
DOI 10.1186/s13073-015-0135-5, PubMed 25873999
Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas
BMC Cancer, 15, 524
DOI 10.1186/s12885-015-1510-8, PubMed 26183823
Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
Mol Oncol, 10 (2), 330-43
DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN
PLoS One, 10 (5), e0126371
DOI 10.1371/journal.pone.0126371, PubMed 25955013
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
Am J Hum Genet, 97 (1), 22-34
DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781
Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair
Nat Genet, 47 (11), 1294-1303
DOI 10.1038/ng.3412, PubMed 26414677
Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair EDITORIAL COMMENT
Obstet. Gynecol. Surv., 70 (12), 758-762
DOI 10.1097/01.ogx.0000473766.71624.99
Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer
Cancer Res, 75 (4), 698-708
DOI 10.1158/0008-5472.CAN-14-2637, PubMed 25649770
Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes
Int J Cancer, 138 (1), 87-97
DOI 10.1002/ijc.29684, PubMed 26174627
Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome
Mol Oncol, 10 (1), 59-72
DOI 10.1016/j.molonc.2015.08.002, PubMed 26321095
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells
Genome Res, 25 (6), 814-24
DOI 10.1101/gr.190470.115, PubMed 25963125
Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium
Hum Genet, 135 (1), 137-54
DOI 10.1007/s00439-015-1616-8, PubMed 26621531
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
Breast Cancer Res, 17 (1), 18
DOI 10.1186/s13058-015-0522-2, PubMed 25849327
Prediction of breast cancer risk based on profiling with common genetic variants
J Natl Cancer Inst, 107 (5)
DOI 10.1093/jnci/djv036, PubMed 25855707
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
J Natl Cancer Inst, 108 (2)
DOI 10.1093/jnci/djv315, PubMed 26586665
MicroRNA let-7b regulates genomic balance by targeting Aurora B kinase
Mol Oncol, 9 (6), 1056-70
DOI 10.1016/j.molonc.2015.01.005, PubMed 25682900
Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2
Hum Mol Genet, 24 (10), 2966-84
DOI 10.1093/hmg/ddv035, PubMed 25652398
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
Genes Dev, 29 (12), 1298-315
DOI 10.1101/gad.263202.115, PubMed 26080815
Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
Mol Oncol, 9 (4), 861-76
DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma
Mol Oncol, 10 (2), 303-16
DOI 10.1016/j.molonc.2015.10.011, PubMed 26590090
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients
BMC Cancer, 15, 978
DOI 10.1186/s12885-015-1957-7, PubMed 26674097
The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
PLoS One, 10 (10), e0139965
DOI 10.1371/journal.pone.0139965, PubMed 26460974
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures
Cancer Res, 75 (12), 2457-67
DOI 10.1158/0008-5472.CAN-14-2012, PubMed 25862352
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
Breast Cancer Res, 17 (1), 44
DOI 10.1186/s13058-015-0548-5, PubMed 25882602
MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth
Mol Oncol, 9 (7), 1287-300
DOI 10.1016/j.molonc.2015.03.001, PubMed 25907805
Publications 2014
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
Cell Rep, 6 (3), 514-27
DOI 10.1016/j.celrep.2013.12.041, PubMed 24462293
Global gene expression analysis reveals a link between NDRG1 and vesicle transport
PLoS One, 9 (1), e87268
DOI 10.1371/journal.pone.0087268, PubMed 24498060
Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
Int J Cancer, 135 (8), 1812-21
DOI 10.1002/ijc.28828, PubMed 24599520
Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk
Hum Genet, 134 (2), 231-45
DOI 10.1007/s00439-014-1515-4, PubMed 25487306
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers
Cancer Cell, 26 (6), 863-879
DOI 10.1016/j.ccell.2014.10.010, PubMed 25490449
Integrated analysis of high-resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients
Int J Cancer, 134 (11), 2615-25
DOI 10.1002/ijc.28606, PubMed 24395279
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
Genome Biol, 15 (8), 435
DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004
Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation
Nat Commun, 4, 4999
DOI 10.1038/ncomms5999, PubMed 25248036
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
Breast Cancer Res, 16 (1), R5
DOI 10.1186/bcr3597, PubMed 24447408
Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
Int J Cancer, 135 (9), 2085-95
DOI 10.1002/ijc.28862, PubMed 24658971
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study
Breast Cancer Res, 16 (3), R51
DOI 10.1186/bcr3662, PubMed 24887515
DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors
Clin Cancer Res, 20 (24), 6357-66
DOI 10.1158/1078-0432.CCR-14-0297, PubMed 25294903
A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients
Clin Cancer Res, 21 (5), 1207-14
DOI 10.1158/1078-0432.CCR-14-2011, PubMed 25547678
Principles and methods of integrative genomic analyses in cancer
Nat Rev Cancer, 14 (5), 299-313
DOI 10.1038/nrc3721, PubMed 24759209
2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
Nat Commun, 5, 4051
DOI 10.1038/ncomms5051, PubMed 24937182
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
Br J Cancer, 110 (8), 2072-80
DOI 10.1038/bjc.2014.113, PubMed 24577056
Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk
Hum Mol Genet, 24 (5), 1478-92
DOI 10.1093/hmg/ddu552, PubMed 25378557
Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53
Mol Cancer Res, 13 (3), 493-501
DOI 10.1158/1541-7786.MCR-14-0387, PubMed 25351767
Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes
PLoS One, 9 (9), e106076
DOI 10.1371/journal.pone.0106076, PubMed 25264628
The multitude of molecular analyses in cancer: the opening of Pandora’s box
Genome Biol, 15 (9), 447
DOI 10.1186/s13059-014-0447-6, PubMed 25316146
Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors
Genes Chromosomes Cancer, 54 (4), 235-48
DOI 10.1002/gcc.22237, PubMed 25546585
Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC
J Proteome Res, 13 (5), 2314-27
DOI 10.1021/pr401092y, PubMed 24669823
Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas
Mol Oncol, 9 (4), 758-71
DOI 10.1016/j.molonc.2014.12.002, PubMed 25579086
TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance
Clin Cancer Res, 20 (13), 3569-80
DOI 10.1158/1078-0432.CCR-13-2943, PubMed 24803582
Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
Br J Cancer, 111 (2), 326-38
DOI 10.1038/bjc.2014.297, PubMed 24901235
Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE)
Methods Mol Biol, 1105, 315-24
DOI 10.1007/978-1-62703-739-6_25, PubMed 24623239
Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
BMC Cancer, 14, 845
DOI 10.1186/1471-2407-14-845, PubMed 25407022
Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG82bc cohort
Clin Cancer Res, 20 (20), 5272-80
DOI 10.1158/1078-0432.CCR-14-0458, PubMed 25149560
Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
Science, 345 (6196), 1251343
DOI 10.1126/science.1251343, PubMed 25082706
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer
Mol Oncol, 9 (1), 115-27
DOI 10.1016/j.molonc.2014.07.019, PubMed 25169931
Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo
Br J Cancer, 111 (11), 2142-51
DOI 10.1038/bjc.2014.524, PubMed 25268374
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status
BMC Cancer, 14, 211
DOI 10.1186/1471-2407-14-211, PubMed 24645668
Publications 2013
Signatures of mutational processes in human cancer
Nature, 500 (7463), 415-21
DOI 10.1038/nature12477, PubMed 23945592
Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors
Genome Biol, 14 (11), R126
DOI 10.1186/gb-2013-14-11-r126, PubMed 24257477
Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data
PLoS One, 8 (1), e53014
DOI 10.1371/journal.pone.0053014, PubMed 23382830
High levels of genomic aberrations in serous ovarian cancers are associated with better survival
PLoS One, 8 (1), e54356
DOI 10.1371/journal.pone.0054356, PubMed 23372714
Improving breast cancer survival analysis through competition-based multidimensional modeling
PLoS Comput Biol, 9 (5), e1003047
DOI 10.1371/journal.pcbi.1003047, PubMed 23671412
SNP in TXNRD2 associated with radiation-induced fibrosis: a study of genetic variation in reactive oxygen species metabolism and signaling
Int J Radiat Oncol Biol Phys, 86 (4), 791-9
DOI 10.1016/j.ijrobp.2013.02.025, PubMed 23597419
Triple-negative breast cancer and the need for new therapeutic targets
Am J Pathol, 183 (4), 1064-1074
DOI 10.1016/j.ajpath.2013.05.033, PubMed 23920327
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
Breast Cancer Res Treat, 141 (3), 397-408
DOI 10.1007/s10549-013-2702-z, PubMed 24091768
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors
BMC Cancer, 13, 456
DOI 10.1186/1471-2407-13-456, PubMed 24093668
Genome-wide association study in breast cancer survivors reveals SNPs associated with gene expression of genes belonging to MHC class I and II
Genomics, 102 (4), 278-87
DOI 10.1016/j.ygeno.2013.07.006, PubMed 23880221
High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth
Mol Oncol, 8 (1), 93-104
DOI 10.1016/j.molonc.2013.10.001, PubMed 24148764
Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer
Breast Cancer Res Treat, 143 (1), 189-201
DOI 10.1007/s10549-013-2796-3, PubMed 24305980
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer
Sci Transl Med, 5 (181), 181re1
DOI 10.1126/scitranslmed.3006112, PubMed 23596205
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1
Am J Hum Genet, 93 (6), 1046-60
DOI 10.1016/j.ajhg.2013.10.026, PubMed 24290378
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium
Hum Mol Genet, 23 (7), 1934-46
DOI 10.1093/hmg/ddt581, PubMed 24242184
Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins
Mol Oncol, 7 (3), 704-18
DOI 10.1016/j.molonc.2013.02.018, PubMed 23562353
Next-generation sequencing of disseminated tumor cells
Front Oncol, 3, 320
DOI 10.3389/fonc.2013.00320, PubMed 24427740
The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors
Mol Oncol, 8 (2), 273-84
DOI 10.1016/j.molonc.2013.11.008, PubMed 24388359
Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
Carcinogenesis, 35 (1), 76-85
DOI 10.1093/carcin/bgt333, PubMed 24104550
Personalized cancer care conference
J Pers Med, 3 (2), 70-81
DOI 10.3390/jpm3020070, PubMed 25562519
Publications 2012
Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers
PLoS One, 7 (6), e38575
DOI 10.1371/journal.pone.0038575, PubMed 22719901
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
Mol Oncol, 7 (1), 130-42
DOI 10.1016/j.molonc.2012.10.005, PubMed 23142657
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Nature, 486 (7403), 346-52
DOI 10.1038/nature10983, PubMed 22522925
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Cell, 148 (1-2), 244-58
DOI 10.1016/j.cell.2011.12.017, PubMed 22265415
Genome-wide association analysis identifies three new breast cancer susceptibility loci
Nat Genet, 44 (3), 312-8
DOI 10.1038/ng.1049, PubMed 22267197
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)
PLoS One, 7 (8), e42380
DOI 10.1371/journal.pone.0042380, PubMed 22879957
Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
Br J Cancer, 107 (10), 1722-8
DOI 10.1038/bjc.2012.461, PubMed 23079576
Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes
BMC Genomics, 13, 199
DOI 10.1186/1471-2164-13-199, PubMed 22616941
Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity
Proc Natl Acad Sci U S A, 109 (16), 6124-9
DOI 10.1073/pnas.1203203109, PubMed 22454501
11q13 is a susceptibility locus for hormone receptor positive breast cancer
Hum Mutat, 33 (7), 1123-32
DOI 10.1002/humu.22089, PubMed 22461340
Mutational processes molding the genomes of 21 breast cancers
Cell, 149 (5), 979-93
DOI 10.1016/j.cell.2012.04.024, PubMed 22608084
The life history of 21 breast cancers
Cell, 149 (5), 994-1007
DOI 10.1016/j.cell.2012.04.023, PubMed 22608083
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation
BMC Genomics, 13, 591
DOI 10.1186/1471-2164-13-591, PubMed 23442169
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
Mol Oncol, 7 (3), 392-401
DOI 10.1016/j.molonc.2012.10.012, PubMed 23253899
AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma
Virchows Arch, 462 (2), 163-73
DOI 10.1007/s00428-012-1347-3, PubMed 23242172
The landscape of cancer genes and mutational processes in breast cancer
Nature, 486 (7403), 400-4
DOI 10.1038/nature11017, PubMed 22722201
19p13.1 is a triple-negative-specific breast cancer susceptibility locus
Cancer Res, 72 (7), 1795-803
DOI 10.1158/0008-5472.CAN-11-3364, PubMed 22331459
Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk
Cancer Epidemiol Biomarkers Prev, 21 (7), 1156-66
DOI 10.1158/1055-9965.EPI-12-0066, PubMed 22454379
Analyzing cancer samples with SNP arrays
Methods Mol Biol, 802, 57-72
DOI 10.1007/978-1-61779-400-1_4, PubMed 22130873
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer
J Clin Oncol, 30 (35), 4308-16
DOI 10.1200/JCO.2012.42.7336, PubMed 23109706
Publications 2011
Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer
Br J Cancer, 105 (1), 9-12
DOI 10.1038/bjc.2011.203, PubMed 21673677
Ischemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue
Mol Oncol, 5 (6), 564-76
DOI 10.1016/j.molonc.2011.08.004, PubMed 21917534
Identification of genetic variation in 11 candidate genes of canine mammary tumour
Vet Comp Oncol, 9 (4), 241-50
DOI 10.1111/j.1476-5829.2010.00250.x, PubMed 22077404
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium
Hum Mol Genet, 20 (16), 3289-303
DOI 10.1093/hmg/ddr228, PubMed 21596841
Identification of fusion genes in breast cancer by paired-end RNA-sequencing
Genome Biol, 12 (1), R6
DOI 10.1186/gb-2011-12-1-r6, PubMed 21247443
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
PLoS One, 6 (2), e16915
DOI 10.1371/journal.pone.0016915, PubMed 21364938
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
Clin Proteomics, 8 (1), 11
DOI 10.1186/1559-0275-8-11, PubMed 21906370
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers
PLoS One, 6 (4), e18064
DOI 10.1371/journal.pone.0018064, PubMed 21533284
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters
Nat Genet, 43 (7), 621-9
DOI 10.1038/ng.848, PubMed 21642992
Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
BMC Cancer, 11, 332
DOI 10.1186/1471-2407-11-332, PubMed 21812955
Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
BMC Med Genomics, 4, 77
DOI 10.1186/1755-8794-4-77, PubMed 22044755
Allele-specific disparity in breast cancer
BMC Med Genomics, 4, 85
DOI 10.1186/1755-8794-4-85, PubMed 22188678
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Cancer Cell, 19 (2), 273-82
DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
Proc Natl Acad Sci U S A, 109 (8), 2802-7
DOI 10.1073/pnas.1108781108, PubMed 21908711
High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer
Int J Cancer, 131 (4), E405-15
DOI 10.1002/ijc.26444, PubMed 21935921
Systems biology and genomics of breast cancer
Cold Spring Harb Perspect Biol, 3 (2)
DOI 10.1101/cshperspect.a003293, PubMed 21047916
Paired distribution of molecular subtypes in bilateral breast carcinomas
Cancer Genet, 204 (2), 96-102
DOI 10.1016/j.cancergencyto.2010.09.012, PubMed 21504707
Insight into the heterogeneity of breast cancer through next-generation sequencing
J Clin Invest, 121 (10), 3810-8
DOI 10.1172/JCI57088, PubMed 21965338
Linear and non-linear dependencies between copy number aberrations and mRNA expression reveal distinct molecular pathways in breast cancer
BMC Bioinformatics, 12, 197
DOI 10.1186/1471-2105-12-197, PubMed 21609452
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
Breast Cancer Res Treat, 133 (3), 865-80
DOI 10.1007/s10549-011-1846-y, PubMed 22048815
Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients
Radiat Oncol, 6, 42
DOI 10.1186/1748-717X-6-42, PubMed 21521514
Combining gene signatures improves prediction of breast cancer survival
PLoS One, 6 (3), e17845
DOI 10.1371/journal.pone.0017845, PubMed 21423775
Publications 2010
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors
Sci Signal, 3 (124), ra43
DOI 10.1126/scisignal.2000876, PubMed 20516477
Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers
Mol Cancer, 9, 173
DOI 10.1186/1476-4598-9-173, PubMed 20594292
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study
J Natl Cancer Inst, 102 (7), 475-83
DOI 10.1093/jnci/djq055, PubMed 20305132
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study
Hum Mutat, 31 (3), E1200-40
DOI 10.1002/humu.21202, PubMed 20104584
Merging transcriptomics and metabolomics--advances in breast cancer profiling
BMC Cancer, 10, 628
DOI 10.1186/1471-2407-10-628, PubMed 21080935
Europe's largest Member Association for Cancer Research
Period. Biol., 112 (4), 483-485
On the molecular biology of breast cancer
Mol Oncol, 4 (3), 171-3
DOI 10.1016/j.molonc.2010.04.007, PubMed 20483673
Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment
Am J Pathol, 176 (3), 1229-40
DOI 10.2353/ajpath.2010.090648, PubMed 20133812
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response
Mol Cancer, 9, 68
DOI 10.1186/1476-4598-9-68, PubMed 20338046
Deciphering normal blood gene expression variation--The NOWAC postgenome study
PLoS Genet, 6 (3), e1000873
DOI 10.1371/journal.pgen.1000873, PubMed 20300640
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance
Pharmacogenomics J, 10 (6), 513-23
DOI 10.1038/tpj.2010.6, PubMed 20157331
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations
Mol Cancer, 9, 113
DOI 10.1186/1476-4598-9-113, PubMed 20482849
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers
Clin Proteomics, 6 (4), 129-51
DOI 10.1007/s12014-010-9055-y, PubMed 21691416
BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
BMC Cancer, 10, 654
DOI 10.1186/1471-2407-10-654, PubMed 21118481
Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
Breast Cancer Res, 12 (4), R65
DOI 10.1186/bcr2632, PubMed 20799965
International network of cancer genome projects
Nature, 464 (7291), 993-8
DOI 10.1038/nature08987, PubMed 20393554
DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables
Mol Oncol, 5 (1), 77-92
DOI 10.1016/j.molonc.2010.11.002, PubMed 21169070
Mutations for the people
EMBO Mol Med, 2 (5), 143-5
DOI 10.1002/emmm.201000071, PubMed 20461736
Blood gene expression profiling of breast cancer survivors experiencing fibrosis
Int J Radiat Oncol Biol Phys, 79 (3), 875-83
DOI 10.1016/j.ijrobp.2010.09.052, PubMed 21129856
The genetics and epigenetics of fatigue
PM R, 2 (5), 456-65
DOI 10.1016/j.pmrj.2010.04.003, PubMed 20656628
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models
BMC Cancer, 10, 433
DOI 10.1186/1471-2407-10-433, PubMed 20716336
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer
Mol Oncol, 4 (4), 357-68
DOI 10.1016/j.molonc.2010.06.007, PubMed 20663721
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer
Breast Cancer Res, 12 (1), R3
DOI 10.1186/bcr2466, PubMed 20056007
In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome
PLoS One, 5 (11), e14002
DOI 10.1371/journal.pone.0014002, PubMed 21124964
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
Mol. Oncol., 4 (2), 169
DOI 10.1016/j.molonc.2010.01.003
High prevalence of germline STK11 mutations in Hungarian Peutz-Jeghers Syndrome patients
BMC Med Genet, 11, 169
DOI 10.1186/1471-2350-11-169, PubMed 21118512
Triple-negative breast cancer: present challenges and new perspectives
Mol Oncol, 4 (3), 209-29
DOI 10.1016/j.molonc.2010.04.006, PubMed 20537966
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients
Sci Transl Med, 2 (38), 38ra47
DOI 10.1126/scitranslmed.3000611, PubMed 20592421
Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer
Mol Oncol, 5 (1), 61-76
DOI 10.1016/j.molonc.2010.11.004, PubMed 21212030
The importance of gene-centring microarray data
Lancet Oncol, 11 (8), 719-20; author reply 720-1
DOI 10.1016/S1470-2045(10)70174-1, PubMed 20688275
Allele-specific copy number analysis of tumors
Proc Natl Acad Sci U S A, 107 (39), 16910-5
DOI 10.1073/pnas.1009843107, PubMed 20837533
Gene expression profiling of peripheral blood cells for early detection of breast cancer
Breast Cancer Res, 12 (1), R7
DOI 10.1186/bcr2472, PubMed 20078854
Publications 2009
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer
Clin Cancer Res, 15 (11), 3654-62
DOI 10.1158/1078-0432.CCR-08-3293, PubMed 19470724
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161
Focal amplification and oncogene dependency of GAB2 in breast cancer
Oncogene, 29 (5), 774-9
DOI 10.1038/onc.2009.364, PubMed 19881546
Association of ESR1 gene tagging SNPs with breast cancer risk
Hum Mol Genet, 18 (6), 1131-9
DOI 10.1093/hmg/ddn429, PubMed 19126777
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study
Breast Cancer Res Treat, 120 (1), 175-83
DOI 10.1007/s10549-009-0455-5, PubMed 19597986
A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide
Clin Cancer Res, 15 (12), 4165-73
DOI 10.1158/1078-0432.CCR-09-0119, PubMed 19509150
Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
Nucleic Acids Res, 37 (12), e89
DOI 10.1093/nar/gkp413, PubMed 19474344
Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors
Pharmacogenomics J, 9 (5), 333-40
DOI 10.1038/tpj.2009.27, PubMed 19546881
Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines
Oncogene, 28 (44), 3926-36
DOI 10.1038/onc.2009.241, PubMed 19684618
Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer
Expert Rev Anticancer Ther, 9 (8), 1115-23
DOI 10.1586/era.09.31, PubMed 19671031
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
PLoS One, 4 (5), e5583
DOI 10.1371/journal.pone.0005583, PubMed 19440550
Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
Mol Oncol, 4 (2), 98-118
DOI 10.1016/j.molonc.2009.12.001, PubMed 20060370
Complex landscapes of somatic rearrangement in human breast cancer genomes
Nature, 462 (7276), 1005-10
DOI 10.1038/nature08645, PubMed 20033038
Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution
Mol Oncol, 3 (3), 214-9
DOI 10.1016/j.molonc.2009.03.001, PubMed 19403344
Publications 2008
A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients
Acta Oncol, 47 (4), 600-7
DOI 10.1080/02841860802047411, PubMed 18465328
Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors
BMC Genomics, 9, 379
DOI 10.1186/1471-2164-9-379, PubMed 18691401
CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer
Mol Oncol, 2 (4), 327-39
DOI 10.1016/j.molonc.2008.09.004, PubMed 19383354
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome
J Pathol, 214 (3), 357-67
DOI 10.1002/path.2278, PubMed 18044827
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation
Mol Syst Biol, 4, 229
DOI 10.1038/msb.2008.65, PubMed 19034270
Variants in the ATM gene associated with a reduced risk of contralateral breast cancer
Cancer Res, 68 (16), 6486-91
DOI 10.1158/0008-5472.CAN-08-0134, PubMed 18701470
Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study
Breast Cancer Res, 10 (1), R13
DOI 10.1186/bcr1859, PubMed 18271962
Comparison of globin RNA processing methods for genome-wide transcriptome analysis from whole blood
Biomark Med, 2 (1), 11-21
DOI 10.2217/17520363.2.1.11, PubMed 20477359
ESR1 gene amplification in breast cancer: a common phenomenon?
Nat Genet, 40 (7), 807-8; author reply 810-2
DOI 10.1038/ng0708-807, PubMed 18583965
SNPs associated with molecular subtypes of breast cancer: on the usefulness of stratified Genome-wide Association Studies (GWAS) in the identification of novel susceptibility loci
Mol Oncol, 2 (1), 12-5
DOI 10.1016/j.molonc.2008.02.003, PubMed 19383324
Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study
Br J Cancer, 98 (4), 728-33
DOI 10.1038/sj.bjc.6604228, PubMed 18253122
Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival
Int J Cancer, 123 (3), 577-85
DOI 10.1002/ijc.23541, PubMed 18498133
Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients
Genes Chromosomes Cancer, 47 (8), 680-96
DOI 10.1002/gcc.20569, PubMed 18398821
GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas
Cancer Res, 68 (14), 5562-71
DOI 10.1158/0008-5472.CAN-07-5828, PubMed 18632608
TP53 mutations in synchronous and metachronous bilateral breast carcinomas
Cancer Genet Cytogenet, 184 (2), 119-21
DOI 10.1016/j.cancergencyto.2008.03.005, PubMed 18617062
Transcriptional networks inferred from molecular signatures of breast cancer
Am J Pathol, 172 (2), 495-509
DOI 10.2353/ajpath.2008.061079, PubMed 18187569
Publications 2007
Relationship between p53 and p27 expression following HER2 signaling
Breast, 16 (6), 597-605
DOI 10.1016/j.breast.2007.05.007, PubMed 17604627
Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas
Breast Cancer Res, 9 (1), R5
DOI 10.1186/bcr1637, PubMed 17224074
Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy
Int J Radiat Oncol Biol Phys, 67 (4), 1163-71
DOI 10.1016/j.ijrobp.2006.11.009, PubMed 17336217
Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence
Radiat Oncol, 2, 25
DOI 10.1186/1748-717X-2-25, PubMed 17623063
Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer
Int J Cancer, 121 (11), 2532-8
DOI 10.1002/ijc.22985, PubMed 17683073
Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status
Cancer Epidemiol Biomarkers Prev, 16 (11), 2269-75
DOI 10.1158/1055-9965.EPI-07-0449, PubMed 18006915
Discovery and validation of breast cancer subtypes (vol 8, pg 101, 2007)
BMC Genomics, 8, 101
DOI 10.1186/1471-2164-8-101
Mutations and polymorphisms of the p21B transcript in breast cancer
Int J Cancer, 121 (4), 908-10
DOI 10.1002/ijc.22777, PubMed 17443496
Transcriptional response to ionizing radiation in human radiation sensitive cell lines
Radiother Oncol, 83 (3), 256-60
DOI 10.1016/j.radonc.2007.04.017, PubMed 17512073
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Breast Cancer Res, 9 (3), R30
DOI 10.1186/bcr1675, PubMed 17504517
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Mol Oncol, 1 (2), 160-71
DOI 10.1016/j.molonc.2007.03.004, PubMed 19383292
Disease-specific genomic analysis: identifying the signature of pathologic biology
Bioinformatics, 23 (8), 957-65
DOI 10.1093/bioinformatics/btm033, PubMed 17277331
Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes
Breast Cancer Res, 9 (6), 113
DOI 10.1186/bcr1784, PubMed 18036273
ABCB1 and GST polymorphisms associated with TP53 status in breast cancer
Pharmacogenet Genomics, 17 (2), 127-36
DOI 10.1097/FPC.0b013e328011abaa, PubMed 17301692
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
Oncogene, 26 (15), 2157-65
DOI 10.1038/sj.onc.1210302, PubMed 17401424
Features of 5'-splice-site efficiency derived from disease-causing mutations and comparative genomics
Genome Res, 18 (1), 77-87
DOI 10.1101/gr.6859308, PubMed 18032726
Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis
Radiother Oncol, 86 (3), 314-20
DOI 10.1016/j.radonc.2007.09.013, PubMed 17963910
Alpha fetoprotein is increasing with age in ataxia-telangiectasia
Eur J Paediatr Neurol, 11 (6), 375-80
DOI 10.1016/j.ejpn.2007.04.001, PubMed 17540590
A retroviral vector for siRNA expression in mammalian cells
Mol Biotechnol, 35 (3), 275-82
DOI 10.1007/BF02686013, PubMed 17652791
Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias
Int J Cancer, 120 (2), 297-302
DOI 10.1002/ijc.22265, PubMed 17066426
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients
Ann Oncol, 18 (5), 964-6
DOI 10.1093/annonc/mdm134, PubMed 17488735
A supervised approach for identifying discriminating genotype patterns and its application to breast cancer data
Bioinformatics, 23 (2), e91-8
DOI 10.1093/bioinformatics/btl298, PubMed 17237111
Publications 2006
Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report
Leukemia, 20 (4), 734-6
DOI 10.1038/sj.leu.2404117, PubMed 16437140
Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters
Mol Cancer, 5, 47
DOI 10.1186/1476-4598-5-47, PubMed 17054774
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer
Genes Chromosomes Cancer, 45 (11), 1033-40
DOI 10.1002/gcc.20366, PubMed 16897746
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
PLoS Med, 3 (3), e47
DOI 10.1371/journal.pmed.0030047, PubMed 16417408
Gene expression profiling of whole-blood samples from women exposed to hormone replacement therapy
Mol Cancer Ther, 5 (4), 868-76
DOI 10.1158/1535-7163.MCT-05-0329, PubMed 16648556
Experimental validation of data mined single nucleotide polymorphisms from several databases and consecutive dbSNP builds
Pharmacogenet Genomics, 16 (3), 207-17
DOI 10.1097/01.fpc.0000194422.12770.fb, PubMed 16495780
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability
Carcinogenesis, 27 (8), 1593-9
DOI 10.1093/carcin/bgi360, PubMed 16474176
Radiation-induced effects on gene expression: an in vivo study on breast cancer
Radiother Oncol, 80 (2), 230-5
DOI 10.1016/j.radonc.2006.07.007, PubMed 16890317
Novel patterns of genome rearrangement and their association with survival in breast cancer
Genome Res, 16 (12), 1465-79
DOI 10.1101/gr.5460106, PubMed 17142309
Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53
Blood, 109 (6), 2589-96
DOI 10.1182/blood-2006-02-004234, PubMed 17105820
Discovery and validation of breast cancer subtypes
BMC Genomics, 7, 231
DOI 10.1186/1471-2164-7-231, PubMed 16965636
Genetic variation in putative regulatory loci controlling gene expression in breast cancer
Proc Natl Acad Sci U S A, 103 (20), 7735-40
DOI 10.1073/pnas.0601893103, PubMed 16684880
Multilocus analysis of SNP and metabolic data within a given pathway
BMC Genomics, 7, 5
DOI 10.1186/1471-2164-7-5, PubMed 16412218
On the proposed association of the ATM variants 5557G>A and IVS38-8T>C and bilateral breast cancer
Int J Cancer, 119 (3), 724-5
DOI 10.1002/ijc.21876, PubMed 16496408
Interaction between p53 staining and high-dose chemotherapy in breast cancer
Clin Cancer Res, 12 (7 Pt 1), 2289
DOI 10.1158/1078-0432.CCR-06-0129, PubMed 16609046
Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes
BMC Cancer, 6, 59
DOI 10.1186/1471-2407-6-59, PubMed 16536878
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
Clin Cancer Res, 12 (4), 1157-67
DOI 10.1158/1078-0432.CCR-05-1029, PubMed 16489069
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer
Clin Cancer Res, 12 (20 Pt 1), 6000-4
DOI 10.1158/1078-0432.CCR-05-2822, PubMed 17062672
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer
Mol Cancer Ther, 5 (11), 2914-8
DOI 10.1158/1535-7163.MCT-06-0126, PubMed 17121939
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms
BMC Genomics, 7, 127
DOI 10.1186/1471-2164-7-127, PubMed 16729877
International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy'
Breast Cancer Res, 8 (6), 303
DOI 10.1186/bcr1609, PubMed 17096863
ATM variants and cancer risk in breast cancer patients from Southern Finland
BMC Cancer, 6, 209
DOI 10.1186/1471-2407-6-209, PubMed 16914028
Analysis of SNP-expression association matrices
J Bioinform Comput Biol, 4 (2), 259-74
DOI 10.1142/s0219720006001953, PubMed 16819783
Publications 2005
High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas
Genes Chromosomes Cancer, 42 (3), 228-37
DOI 10.1002/gcc.20128, PubMed 15578687
Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas
Biotechniques, 39 (5), 755-61
DOI 10.2144/000112000, PubMed 16312222
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
BMC Cancer, 5, 134
DOI 10.1186/1471-2407-5-134, PubMed 16229746
Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications
Clin Cancer Res, 11 (2 Pt 2), 878s-83s
PubMed 15701881
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer
J Steroid Biochem Mol Biol, 95 (1-5), 105-11
DOI 10.1016/j.jsbmb.2005.04.028, PubMed 16023338
Genomics in breast cancer-therapeutic implications
Nat Clin Pract Oncol, 2 (1), 26-33
DOI 10.1038/ncponc0072, PubMed 16264853
Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer
Breast Cancer Res Treat, 94 (2), 145-52
DOI 10.1007/s10549-005-7697-7, PubMed 16261413
Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia
Br J Cancer, 93 (2), 260-5
DOI 10.1038/sj.bjc.6602658, PubMed 15942625
Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts
Radiother Oncol, 77 (3), 231-40
DOI 10.1016/j.radonc.2005.09.020, PubMed 16297999
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells
Breast Cancer Res, 7 (5), R634-44
DOI 10.1186/bcr1203, PubMed 16168108
Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis
Methods Mol Biol, 291, 207-16
DOI 10.1385/1-59259-840-4:207, PubMed 15502225
Analysis of SNP-expression association matrices
Proc IEEE Comput Syst Bioinform Conf, 135-43
DOI 10.1109/csb.2005.14, PubMed 16447971
PIK3CA mutations in advanced ovarian carcinomas
Hum Mutat, 25 (3), 322
DOI 10.1002/humu.9316, PubMed 15712344
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
Am J Clin Pathol, 124 (3), 392-401
DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507
Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin
Oncol Rep, 13 (3), 525-30
PubMed 15706428
Publications 2004
Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study
Breast Cancer Res, 6 (3), R199-214
DOI 10.1186/bcr771, PubMed 15084244
CGH-Explorer: a program for analysis of array-CGH data
Bioinformatics, 21 (6), 821-2
DOI 10.1093/bioinformatics/bti113, PubMed 15531610
The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents
Clin Exp Immunol, 137 (1), 179-86
DOI 10.1111/j.1365-2249.2004.02492.x, PubMed 15196260
Alternative splicing and mutation status of CHEK2 in stage III breast cancer
Oncogene, 23 (52), 8535-44
DOI 10.1038/sj.onc.1207928, PubMed 15361853
Expression profiling of breast cancer: From molecular portraits to clinical utility.
In Oncogenomics: Molecular approaches to cancer (Brenner C, Duggan DJ, eds.), John Wiley & Sons, Inc., New York
PublikaID 67, ISBN 0-471-22592-4
Cell-type-specific responses to chemotherapeutics in breast cancer
Cancer Res, 64 (12), 4218-26
DOI 10.1158/0008-5472.CAN-04-0107, PubMed 15205334
Mutation of GATA3 in human breast tumors
Oncogene, 23 (46), 7669-78
DOI 10.1038/sj.onc.1207966, PubMed 15361840
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Br J Cancer, 90 (3), 678-85
DOI 10.1038/sj.bjc.6601537, PubMed 14760384
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
DOI 10.1002/humu.20055, PubMed 15221786
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast
Mol Biol Cell, 15 (6), 2523-36
DOI 10.1091/mbc.e03-11-0786, PubMed 15034139
Publications 2003
ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer
Br J Cancer, 89 (8), 1513-6
DOI 10.1038/sj.bjc.6601289, PubMed 14562025
Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer
Hum Mutat, 21 (5), 542-50
DOI 10.1002/humu.10206, PubMed 12673797
TP53 and breast cancer
Hum Mutat, 21 (3), 292-300
DOI 10.1002/humu.10174, PubMed 12619115
Genetic profiling of breast cancer: from molecular portraits to clinical utility
Int J Biol Markers, 18 (1), 54-6
DOI 10.1177/172460080301800109, PubMed 12699064
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer
Clin Cancer Res, 9 (15), 5582-8
PubMed 14654539
X chromosome inactivation in cervical cancer patients
Cancer Genet Cytogenet, 146 (1), 73-6
DOI 10.1016/s0165-4608(03)00152-3, PubMed 14499700
BUB1 infrequently mutated in human breast carcinomas
Hum Mutat, 22 (5), 420
DOI 10.1002/humu.9194, PubMed 14517964
ATM is not required in somatic hypermutation of VH, but is involved in the introduction of mutations in the switch mu region
J Immunol, 170 (7), 3707-16
DOI 10.4049/jimmunol.170.7.3707, PubMed 12646636
Gene expression patterns in ovarian carcinomas
Mol Biol Cell, 14 (11), 4376-86
DOI 10.1091/mbc.e03-05-0279, PubMed 12960427
Repeated observation of breast tumor subtypes in independent gene expression data sets
Proc Natl Acad Sci U S A, 100 (14), 8418-23
DOI 10.1073/pnas.0932692100, PubMed 12829800
Multiplex single-tube screening for mutations in the Nijmegen Breakage Syndrome (NBS1) gene in Hodgkin's and non-Hodgkin's lymphoma patients of Slavic origin
Eur J Hum Genet, 11 (5), 416-9
DOI 10.1038/sj.ejhg.5200972, PubMed 12734548
Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer
Breast Cancer Res, 6 (2), R46-55
DOI 10.1186/bcr746, PubMed 14979917
Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy
Eur J Cancer, 39 (4), 438-46
DOI 10.1016/s0959-8049(02)00732-3, PubMed 12751373
Publications 2002
ATM mutations in Finnish breast cancer patients
J Med Genet, 39 (3), 192-6
DOI 10.1136/jmg.39.3.192, PubMed 11897822
Workshop on The Epidemiology of the ATM Gene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002
Breast Cancer Res, 4 (6), 249-52
DOI 10.1186/bcr551, PubMed 12473172
Mismatch detection using heteroduplex analysis
Curr Protoc Hum Genet, Chapter 7, Unit 7.3
DOI 10.1002/0471142905.hg0703s33, PubMed 18428333
Expression array technology in the diagnosis and treatment of breast cancer
Mol Interv, 2 (2), 101-9
DOI 10.1124/mi.2.2.101, PubMed 14993355
BRCA1 mutation screening using restriction endonuclease fingerprinting-single-strand conformation polymorphism in an automated capillary electrophoresis system
Electrophoresis, 23 (24), 4085-91
DOI 10.1002/elps.200290025, PubMed 12481264
High frequency of skewed X inactivation in young breast cancer patients
J Med Genet, 39 (1), 30-3
DOI 10.1136/jmg.39.1.30, PubMed 11826021
The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas
Cancer Epidemiol Biomarkers Prev, 11 (12), 1684-8
PubMed 12496062
Different genetic components in the Norwegian population revealed by the analysis of mtDNA and Y chromosome polymorphisms
Eur J Hum Genet, 10 (9), 521-9
DOI 10.1038/sj.ejhg.5200834, PubMed 12173029
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors
Proc Natl Acad Sci U S A, 99 (20), 12963-8
DOI 10.1073/pnas.162471999, PubMed 12297621
Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis
BMC Genomics, 3 (1), 31
DOI 10.1186/1471-2164-3-31, PubMed 12445333
Publications 2001
Automated constant denaturant capillary electrophoresis applied for detection of KRAS exon 1 mutations
Biotechniques, 30 (5), 972-5
DOI 10.2144/01305st01, PubMed 11355359
Detection of mutations by denaturing gradient gel electrophoresis
Curr Protoc Hum Genet, Chapter 7, Unit 7.5
DOI 10.1002/0471142905.hg0705s17, PubMed 18428306
Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas
Anal Cell Pathol, 23 (2), 45-9
DOI 10.1155/2001/521873, PubMed 11904459
[Microarray technology--potential in cancer research]
Tidsskr Nor Laegeforen, 121 (21), 2498-503
PubMed 11875927
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
Cancer Res, 61 (6), 2505-12
PubMed 11289122
Livmorhalskreft og arvelighet med fokus på HLA-systemet
In Medicinsk årbog, Norli, Oslo, 2001, s. 121-128
BIBSYS 042195993
Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival
Proc Natl Acad Sci U S A, 98 (14), 7952-7
DOI 10.1073/pnas.151241198, PubMed 11438741
Hypervariable area in the 5' flanking region of GSTP1, previously reported as a minisatellite ATAAA repeat
Hum Mutat, 17 (3), 238-9
DOI 10.1002/humu.17, PubMed 11241854
[Genetic polymorphism and variability of steroid hormone metabolism: connection with risk of developing breast neoplasms]
Vopr Onkol, 47 (2), 156-9
PubMed 11383450
High-throughput methods for detection of genetic variation
Biotechniques, 30 (2), 318-22, 324, 326 passim
DOI 10.2144/01302tt01, PubMed 11233601
Genetic susceptibility and environmental estrogen-like compounds
Mutat Res, 482 (1-2), 77-82
DOI 10.1016/s0027-5107(01)00212-3, PubMed 11535251
Microarrays in primary breast cancer--lessons from chemotherapy studies
Endocr Relat Cancer, 8 (3), 259-63
DOI 10.1677/erc.0.0080259, PubMed 11566617
Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries
J Natl Cancer Inst, 93 (2), 121-7
DOI 10.1093/jnci/93.2.121, PubMed 11208881
Low frequency of E-cadherin alterations in familial breast cancer
Breast Cancer Res, 3 (3), 199-207
DOI 10.1186/bcr295, PubMed 11305955
[Measurement of gene activity by DNA microarrays]
Tidsskr Nor Laegeforen, 121 (10), 1225-8
PubMed 11402749
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Proc Natl Acad Sci U S A, 98 (19), 10869-74
DOI 10.1073/pnas.191367098, PubMed 11553815
Detection of mutations by single-strand conformation polymorphism (SSCP) analysis and SSCP-hybrid methods
Curr Protoc Hum Genet, Chapter 7, Unit 7.4
DOI 10.1002/0471142905.hg0704s15, PubMed 18428305
Publications 2000
Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]
J Pathol, 190 (1), 15-9
DOI 10.1002/(SICI)1096-9896(200001)190:1<15::AID-PATH489>3.0.CO;2-L, PubMed 10640987
Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival
Int J Cancer, 88 (2), 217-22
DOI 10.1002/1097-0215(20001015)88:2<217::aid-ijc11>3.0.co;2-i, PubMed 11004671
Recurrent fallopian tube carcinoma: TP53 mutation and clinical course
Int J Gynecol Pathol, 19 (2), 145-51
DOI 10.1097/00004347-200004000-00008, PubMed 10782411
GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients
Carcinogenesis, 21 (1), 49-54
DOI 10.1093/carcin/21.1.49, PubMed 10607733
Enhanced detection of mutations in BRCA1 exon 11 using restriction endonuclease fingerprinting-single-strand conformation polymorphism
J Mol Med (Berl), 78 (10), 580-7
DOI 10.1007/s001090000147, PubMed 11199332
Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism
Mutat Res, 462 (2-3), 323-33
DOI 10.1016/s1383-5742(00)00018-1, PubMed 10767642
Genetic variants of CYP19 (aromatase) and breast cancer risk
Oncogene, 19 (10), 1329-33
DOI 10.1038/sj.onc.1203425, PubMed 10713674
Association between apolipoprotein E genotypes and cancer risk in patients with acquired immunodeficiency syndrome
Cancer Detect Prev, 24 (5), 496-9
PubMed 11129992
Characterization of ATM mutations in 41 Nordic families with ataxia telangiectasia
Hum Mutat, 16 (3), 232-46
DOI 10.1002/1098-1004(200009)16:3<232::AID-HUMU6>3.0.CO;2-L, PubMed 10980530
Screening breast cancer patients for Norwegian ATM mutations
Br J Cancer, 83 (12), 1650-3
DOI 10.1054/bjoc.2000.1519, PubMed 11104561
Molecular portraits of human breast tumours
Nature, 406 (6797), 747-52
DOI 10.1038/35021093, PubMed 10963602
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma
Int J Cancer, 89 (4), 313-24
DOI 10.1002/1097-0215(20000720)89:4<313::aid-ijc1>3.0.co;2-d, PubMed 10956404
Publications 1999
BRCA1 screening in patients with a family history of breast or ovarian cancer
Genet Test, 3 (2), 223-6
DOI 10.1089/gte.1999.3.223, PubMed 10464672
No association between radiosensitivity and TP53 status, G1 arrest or protein levels of p53, myc, ras or raf in human melanoma lines
Int J Radiat Biol, 75 (9), 1149-60
DOI 10.1080/095530099139629, PubMed 10528923
Detection of low-frequency mutations in exon 8 of the TP53 gene by constant denaturant capillary electrophoresis (CDCE)
Biotechniques, 27 (1), 128-34
DOI 10.2144/99271rr01, PubMed 10407675
p53 polymorphism and cervical cancer
Lancet, 354 (9189), 1561-2
DOI 10.1016/S0140-6736(05)76596-X, PubMed 10551531
TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas
Anticancer Res, 19 (4C), 3433-8
PubMed 10629631
Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium
Genes Chromosomes Cancer, 25 (3), 212-21
DOI 10.1002/(SICI)1098-2264(199907)25:3<212::AID-GCC3>3.3.CO;2-7, PubMed 10379867
CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1
Cancer Res, 59 (12), 2825-8
PubMed 10383140
Allelic imbalance at chromosome region 11q23 in cervical carcinomas
Eur J Cancer, 35 (4), 659-63
DOI 10.1016/s0959-8049(98)00413-4, PubMed 10492643
TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus
J Pathol, 187 (5), 556-62
DOI 10.1002/(SICI)1096-9896(199904)187:5<556::AID-PATH294>3.0.CO;2-Y, PubMed 10398121
Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma
J Pathol, 189 (4), 504-13
DOI 10.1002/(SICI)1096-9896(199912)189:4<504::AID-PATH483>3.0.CO;2-A, PubMed 10629550
Publications 1998
Chromosome region 8p11-p21: refined mapping and molecular alterations in breast cancer
Genes Chromosomes Cancer, 22 (3), 186-99
DOI 10.1002/(sici)1098-2264(199807)22:3<186::aid-gcc4>3.0.co;2-s, PubMed 9624530
[Diagnostic molecular biology in breast cancer]
Tidsskr Nor Laegeforen, 118 (15), 2366-9
PubMed 9691806
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening
Hum Mutat, 11 (2), 166-74
DOI 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X, PubMed 9482581
Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction
Mutat Res, 403 (1-2), 103-12
DOI 10.1016/s0027-5107(98)00057-8, PubMed 9726011
Expression of cyclin Ds in relation to p53 status in human breast carcinomas
Virchows Arch, 433 (3), 223-8
DOI 10.1007/s004280050240, PubMed 9769125
E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma
J Pathol, 185 (3), 262-6
DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y, PubMed 9771479
[Hereditary cancer]
Tidsskr Nor Laegeforen, 118 (12), 1873-7
PubMed 9638057
TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival
Clin Cancer Res, 4 (1), 203-10
PubMed 9516972
[Molecular biology. Basis for increased understanding of diseases and improved diagnostics]
Tidsskr Nor Laegeforen, 118 (11), 1681
PubMed 9621751
Association of p53 accumulation with TP53 mutations, loss of heterozygosity at 17p13, and DNA ploidy status in 273 colorectal carcinomas
Diagn Mol Pathol, 7 (4), 215-23
DOI 10.1097/00019606-199808000-00006, PubMed 9917132
[Molecular genetic diagnostics. Technology for detecting mutations in DNA]
Tidsskr Nor Laegeforen, 118 (11), 1730-6
PubMed 9621763
p53 polymorphism and risk of cervical cancer
Nature, 396 (6711), 530-1; author reply 532
DOI 10.1038/25034, PubMed 9859987
An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with the HLA-DQA1*0102-DQB1*0602 haplotype: a population-based case-control study of Norwegian women
Int J Cancer, 76 (1), 19-24
DOI 10.1002/(sici)1097-0215(19980330)76:1<19::aid-ijc4>3.0.co;2-0, PubMed 9533756
Ki-ras mutations and prognosis in colorectal cancer
Eur J Cancer, 34 (4), 518-21
DOI 10.1016/s0959-8049(97)10111-3, PubMed 9713302
High-throughput screening for known mutations by automated analysis of single sequencing reactions
Biotechniques, 24 (5), 832-5
DOI 10.2144/98245dt04, PubMed 9591134
A rare CYP19 (aromatase) variant may increase the risk of breast cancer
Pharmacogenetics, 8 (1), 43-8
DOI 10.1097/00008571-199802000-00006, PubMed 9511180
The APC gene I1307K variant is rare in Norwegian patients with familial and sporadic colorectal or breast cancer
Cancer Res, 58 (14), 2923-4
PubMed 9679946
Identical mutation in 55% of the ATM alleles in 11 Norwegian AT families: evidence for a founder effect
Eur J Hum Genet, 6 (3), 235-44
DOI 10.1038/sj.ejhg.5200181, PubMed 9781027
Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients
Pharmacogenetics, 8 (5), 441-7
DOI 10.1097/00008571-199810000-00009, PubMed 9825836
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters
Cancer Res, 58 (5), 1004-12
PubMed 9500463
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
Br J Cancer, 78 (3), 375-81
DOI 10.1038/bjc.1998.502, PubMed 9703286
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases
Breast Cancer Res Treat, 48 (3), 259-64
DOI 10.1023/a:1005953519972, PubMed 9598872
Truncating somatic mutation in exon 15 of the APC gene is a rare event in human breast carcinomas. Mutations in brief no. 179. Online
Hum Mutat, 12 (3), 215
PubMed 10660330
Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines
Br J Cancer, 77 (10), 1573-9
DOI 10.1038/bjc.1998.259, PubMed 9635831
Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations
Am J Hum Genet, 62 (1), 86-97
DOI 10.1086/301673, PubMed 9443866
Publications 1997
Screening for ESR mutations in breast and ovarian cancer patients
Hum Mutat, 9 (6), 531-6
DOI 10.1002/(SICI)1098-1004(1997)9:6<531::AID-HUMU6>3.0.CO;2-4, PubMed 9195227
Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors
Int J Cancer, 74 (6), 664-9
DOI 10.1002/(sici)1097-0215(19971219)74:6<664::aid-ijc18>3.0.co;2-5, PubMed 9421366
Interaction between bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53
Int J Cancer, 73 (1), 38-41
DOI 10.1002/(sici)1097-0215(19970926)73:1<38::aid-ijc7>3.0.co;2-2, PubMed 9334807
Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas
Virchows Arch, 431 (5), 317-21
DOI 10.1007/s004280050105, PubMed 9463572
Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas
J Pathol, 181 (2), 140-5
DOI 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A, PubMed 9120716
Temporal Temperature Gradient Gel Electrophoresis on the DCode™ System A Comparison to DGGE and CDGE in Mutation Screening
In Bio Rad Bulletin, BioRad, 2133, 12-13
PublikaID 33
Loss of heterozygosity at 7q31 in breast cancer: results from an International Collaborative Study Group. The Breast Cancer Somatic Genetics Consortium
Genes Chromosomes Cancer, 18 (3), 193-9
PubMed 9071572
Absence of p21 expression is associated with abnormal p53 in human breast carcinomas
Br J Cancer, 76 (4), 480-5
DOI 10.1038/bjc.1997.413, PubMed 9275025
A segregation analysis of testicular cancer based on Norwegian and Swedish families
Br J Cancer, 75 (7), 1084-7
DOI 10.1038/bjc.1997.185, PubMed 9083348
Microsatellite instability in cervical and endometrial carcinomas
Int J Cancer, 70 (5), 499-501
DOI 10.1002/(sici)1097-0215(19970304)70:5<499::aid-ijc1>3.0.co;2-t, PubMed 9052745
A comparison of different modes for the detection of p53 protein accumulation. A study of bladder cancer
Pathol Res Pract, 193 (7), 471-8
DOI 10.1016/s0344-0338(97)80099-4, PubMed 9342752
Improved electrophoretic separation of polymorphic short tandem repeats in agarose gels using bis-benzimide
Biotechniques, 23 (4), 634-6
DOI 10.2144/97234bm18, PubMed 9343680
Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM
Genes Chromosomes Cancer, 18 (3), 175-80
DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.3.CO;2-R, PubMed 9071570
Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer
Int J Cancer, 74 (1), 138-40
DOI 10.1002/(sici)1097-0215(19970220)74:1<138::aid-ijc23>3.0.co;2-a, PubMed 9036883
TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas
J Pathol, 181 (2), 158-65
DOI 10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8, PubMed 9120719
Genetic services in Norway
Eur J Hum Genet, 5 Suppl 2, 130-4
PubMed 9450210
Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families
Br J Cancer, 75 (8), 1201-4
DOI 10.1038/bjc.1997.205, PubMed 9099970
Screening of 229 family cancer patients for a germline estrogen receptor gene (ESR) base mutation
Hum Mutat, 9 (3), 289
DOI 10.1002/(SICI)1098-1004(1997)9:3<289::AID-HUMU15>3.0.CO;2-Z, PubMed 9090537
A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region
Cancer Res, 57 (12), 2474-7
PubMed 9192828
Publications 1996
A common BRCA1 mutation in Norwegian breast and ovarian cancer families?
Am J Hum Genet, 59 (2), 486-7
PubMed 8755943
TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast
Breast Cancer Res Treat, 41 (2), 103-9
DOI 10.1007/BF01807155, PubMed 8944328
Familial testicular cancer in Norway and southern Sweden
Br J Cancer, 73 (7), 964-9
DOI 10.1038/bjc.1996.173, PubMed 8611416
Risk of cancer in relatives of testicular cancer patients
Br J Cancer, 73 (7), 970-3
DOI 10.1038/bjc.1996.174, PubMed 8611417
Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis
Cancer Res, 56 (20), 4778-81
PubMed 8840998
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
Br J Cancer, 73 (8), 909-16
DOI 10.1038/bjc.1996.181, PubMed 8611425
Alterations of p53 and expression of WAF1/p21 in human thyroid tumors
Thyroid, 6 (1), 1-9
DOI 10.1089/thy.1996.6.1, PubMed 8777377
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
Nat Med, 2 (7), 811-4
DOI 10.1038/nm0796-811, PubMed 8673929
Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome
Acta Oncol, 35 Suppl 5, 5-8
DOI 10.3109/02841869609083960, PubMed 9142957
Publications 1995
Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection
Diagn Mol Pathol, 4 (3), 203-11
DOI 10.1097/00019606-199509000-00008, PubMed 7493140
Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour
Acta Oncol, 34 (4), 499-504
DOI 10.3109/02841869509094014, PubMed 7605658
TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue
J Pathol, 176 (3), 299-308
DOI 10.1002/path.1711760312, PubMed 7674092
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains
Genes Chromosomes Cancer, 14 (1), 71-5
DOI 10.1002/gcc.2870140113, PubMed 8527388
Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas
Hum Mol Genet, 4 (11), 2065-72
DOI 10.1093/hmg/4.11.2065, PubMed 8589682
Breast cancer information on the web
Nat Genet, 11 (3), 238-9
DOI 10.1038/ng1195-238, PubMed 7581445
Association studies of estrogen receptor polymorphisms in a Norwegian testicular cancer population
Cancer Epidemiol Biomarkers Prev, 4 (2), 123-6
PubMed 7742719
Localization of an ataxia-telangiectasia gene to an approximately 500-kb interval on chromosome 11q23.1: linkage analysis of 176 families by an international consortium
Am J Hum Genet, 57 (1), 112-9
PubMed 7611279
Deletion of 1p loci and microsatellite instability in colorectal polyps
Genes Chromosomes Cancer, 14 (3), 182-8
DOI 10.1002/gcc.2870140305, PubMed 8589034
[Early diagnosis of colorectal tumors]
Tidsskr Nor Laegeforen, 115 (26), 3231-2
PubMed 7482447
Molecular genetic changes in human male germ cell tumors
Lab Invest, 73 (5), 606-14
PubMed 7474934
Alterations at chromosome 17 loci in peripheral nerve sheath tumors
J Neuropathol Exp Neurol, 54 (1), 65-73
DOI 10.1097/00005072-199501000-00008, PubMed 7815081
TP53 gene mutations and protein accumulation in primary vaginal carcinomas
Br J Cancer, 72 (1), 129-33
DOI 10.1038/bjc.1995.288, PubMed 7599041
Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology
Pharmacogenetics, 5 (4), 215-23
DOI 10.1097/00008571-199508000-00005, PubMed 8528268
TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis
Eur J Cancer, 31A (11), 1856-61
DOI 10.1016/0959-8049(95)00399-4, PubMed 8541113
Publications 1994
Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility
Hum Genet, 94 (6), 665-70
DOI 10.1007/BF00206961, PubMed 7989041
Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations
Cancer Res, 54 (15), 4200-6
PubMed 8033152
TP53 allele loss, mutations and expression in malignant melanoma
Br J Cancer, 69 (2), 253-9
DOI 10.1038/bjc.1994.48, PubMed 7905277
Genetic haplotyping of ataxia-telangiectasia families localizes the major gene to an approximately 850 kb region on chromosome 11q23.1
Int J Radiat Biol, 66 (6 Suppl), S57-62
DOI 10.1080/09553009414551861, PubMed 7836853
Association studies of a polymorphism in the Wilms' tumor 1 locus in Norwegian patients with testicular cancer
Int J Cancer, 58 (4), 523-6
DOI 10.1002/ijc.2910580412, PubMed 8056449
DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis
Cancer Epidemiol Biomarkers Prev, 3 (6), 479-86
PubMed 8000298
Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma
J Clin Oncol, 12 (5), 925-30
DOI 10.1200/JCO.1994.12.5.925, PubMed 8164043
[Molecular pathology. A new diagnostic dimension]
Tidsskr Nor Laegeforen, 114 (26), 3047-8
PubMed 7974419
Genetic alterations of chromosome 17 in human breast carcinoma studied by fluorescence in situ hybridization and molecular DNA techniques
Cancer Genet Cytogenet, 75 (1), 1-5
DOI 10.1016/0165-4608(94)90207-0, PubMed 8039157
Intragenic reorganization of RB1 in a complex (4;13) rearrangement demonstrated by FISH
Cytogenet Cell Genet, 65 (4), 268-71
DOI 10.1159/000133645, PubMed 8258302
p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer
Cancer Res, 54 (6), 1551-5
PubMed 8137262
p53 alterations in gastric carcinoma: a study of 56 primary tumors and 204 nodal metastases
Cancer Genet Cytogenet, 75 (1), 45-50
DOI 10.1016/0165-4608(94)90214-3, PubMed 8039163
Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls
Pharmacogenetics, 4 (2), 47-57
PubMed 8081413
Genome scanning of breast cancers by two-dimensional DNA typing
Br J Cancer, 69 (1), 84-92
DOI 10.1038/bjc.1994.13, PubMed 8286216
Publications 1993
Prognostic significance of TP53 alterations in breast carcinoma
Br J Cancer, 68 (3), 540-8
DOI 10.1038/bjc.1993.383, PubMed 8102535
p53 abnormalities in different subtypes of human sarcomas
Cancer Res, 53 (3), 468-71
PubMed 8425179
[The 1993 Nobel Prize in chemistry--polymerase chain reaction and directed mutagenesis]
Tidsskr Nor Laegeforen, 113 (30), 3668-9
PubMed 8278946
Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques
Hum Mutat, 2 (1), 58-66
DOI 10.1002/humu.1380020111, PubMed 8477265
No germline TP53 mutations detected in familial and bilateral testicular cancer
Genes Chromosomes Cancer, 6 (2), 92-7
DOI 10.1002/gcc.2870060205, PubMed 7680893
Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas
J Pathol, 171 (2), 105-14
DOI 10.1002/path.1711710207, PubMed 8283348
Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri
J Pathol, 169 (1), 21-6
DOI 10.1002/path.1711690105, PubMed 8433212
Genome scanning of human breast carcinomas using micro- and minisatellite core probes
Genomics, 17 (1), 66-75
DOI 10.1006/geno.1993.1284, PubMed 8104870
Frequent loss of 11p13 and 11p15 loci in male germ cell tumours
Genes Chromosomes Cancer, 7 (2), 96-101
DOI 10.1002/gcc.2870070206, PubMed 7687459
Genetic alterations in a malignant schwannoma from a patient with neurofibromatosis (NF1)
Pathol Res Pract, 189 (4), 465-71; discussion 471-4
DOI 10.1016/S0344-0338(11)80339-0, PubMed 8351250
The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic alterations on chromosome 17
Br J Cancer, 67 (1), 88-92
DOI 10.1038/bjc.1993.14, PubMed 8094008
The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables
Br J Cancer, 67 (1), 93-8
DOI 10.1038/bjc.1993.15, PubMed 8427784
Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis
Acta Oncol, 32 (3), 289-94
DOI 10.3109/02841869309093597, PubMed 8100712
K-ras oncogene codon 12 point mutations in testicular cancer
Environ Health Perspect, 101 Suppl 3 (Suppl 3), 185-7
DOI 10.1289/ehp.101-1521158, PubMed 8143614
Rare Ha-ras1 alleles and predisposition to testicular cancer
Int J Cancer, 53 (6), 938-40
DOI 10.1002/ijc.2910530612, PubMed 8097187
Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE)
Hum Mutat, 2 (4), 274-85
DOI 10.1002/humu.1380020407, PubMed 8401536
Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor
Cancer Res, 53 (7), 1637-41
PubMed 8453635
Publications 1992
Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas
Genes Chromosomes Cancer, 4 (2), 113-21
DOI 10.1002/gcc.2870040203, PubMed 1373310
Oncogenesis in ovarian cancer
Acta Obstet Gynecol Scand Suppl, 155, 25-30
DOI 10.1111/j.1600-0412.1992.tb00004.x, PubMed 1502889
Role of genetic factors in breast cancer susceptibility
Acta Oncol, 31 (2), 151-5
DOI 10.3109/02841869209088896, PubMed 1622629
Screening for germ line TP53 mutations in breast cancer patients
Cancer Res, 52 (11), 3234-6
PubMed 1591732
Papillomaviruses, p53, and cervical cancer
Lancet, 339 (8805), 1350-1
PubMed 1350005
c-erbB-2 expression in primary gastric carcinomas and their metastases
Mod Pathol, 5 (4), 384-90
PubMed 1353880
Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein
Proc Natl Acad Sci U S A, 89 (14), 6413-7
DOI 10.1073/pnas.89.14.6413, PubMed 1631137
HLA antigens and cervical carcinoma
Nature, 356 (6364), 23
DOI 10.1038/356023a0, PubMed 1538776
A TP53 mutation detected in cells established from an osteosarcoma, but not in the retinoblastoma of a patient with bilateral retinoblastoma and multiple primary osteosarcomas
Cancer Genet Cytogenet, 64 (2), 178-82
DOI 10.1016/0165-4608(92)90352-9, PubMed 1336709
No alterations in exon 21 of the RB1 gene in sarcomas and carcinomas of the breast, colon, and lung
Genes Chromosomes Cancer, 5 (2), 97-103
DOI 10.1002/gcc.2870050202, PubMed 1381957
Detection of DNA variation in cancer
Pharmacogenetics, 2 (6), 317-28
DOI 10.1097/00008571-199212000-00011, PubMed 1306133
Detection of ras gene mutations in human lung cancer: comparison of two screening assays based on the polymerase chain reaction
Environ Health Perspect, 98, 183-5
DOI 10.1289/ehp.9298183, PubMed 1486847
Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors
J Natl Cancer Inst, 84 (14), 1100-8
DOI 10.1093/jnci/84.14.1100, PubMed 1619684
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms
N Engl J Med, 326 (20), 1309-15
DOI 10.1056/NEJM199205143262002, PubMed 1565144
Chromosome 12 in human testicular cancer: dosage changes and their parental origin
Cancer Genet Cytogenet, 64 (1), 21-6
DOI 10.1016/0165-4608(92)90316-z, PubMed 1458445
Allele diversity of the H-ras-1 variable number of tandem repeats in Norwegian lung cancer patients
Environ Health Perspect, 98, 187-9
DOI 10.1289/ehp.9298187, PubMed 1362538
P53 mutations in gastric carcinomas
Br J Cancer, 65 (5), 708-10
DOI 10.1038/bjc.1992.149, PubMed 1586599
Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE)
Mutat Res, 269 (1), 41-53
DOI 10.1016/0027-5107(92)90159-y, PubMed 1381470
Publications 1991
Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations
Proc Natl Acad Sci U S A, 88 (19), 8405-9
DOI 10.1073/pnas.88.19.8405, PubMed 1924299
Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection
Mutat Res, 263 (1), 61
DOI 10.1016/0165-7992(91)90036-4, PubMed 2034242
Chromosome 13 alterations in osteosarcoma cell lines derived from a patient with previous retinoblastoma
Cancer Genet Cytogenet, 57 (1), 31-40
DOI 10.1016/0165-4608(91)90186-x, PubMed 1684533
Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection
Mutat Res, 262 (1), 63-71
DOI 10.1016/0165-7992(91)90108-g, PubMed 1702518
Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis
Br J Cancer, 64 (3), 475-80
DOI 10.1038/bjc.1991.334, PubMed 1911187
The c-erbB-2 protein in primary and metastatic breast carcinomas
Ultrastruct Pathol, 15 (3), 281-9
DOI 10.3109/01913129109021890, PubMed 1678562
C-erbB-2 protein and neuroendocrine expression in breast carcinomas
Anticancer Res, 11 (1), 161-7
PubMed 1673329
Altered dosage of the sex chromosomes in human testicular cancer: a molecular genetic study
Int J Cancer, 47 (4), 518-22
DOI 10.1002/ijc.2910470408, PubMed 1995482
Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population
Pharmacogenetics, 1 (1), 20-5
DOI 10.1097/00008571-199110000-00004, PubMed 1726950
Publications 1990
THE USE OF GENE TECHNOLOGY IN THE CLINICAL LABORATORY
Scand. J. Clin. Lab. Invest., 50 202, 9-13
The use of gene technology in the clinical laboratory
Scand J Clin Lab Invest Suppl, 202, 9-13
PubMed 2075459
Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia
Genes Chromosomes Cancer, 2 (4), 339-40
DOI 10.1002/gcc.2870020412, PubMed 2268581
Screening for base mutations in the PAH and HPRT loci using the polymerase chain reaction (PCR) in combination with denaturing gradient gel electrophoresis (DGGE)
Prog Clin Biol Res, 340A, 389-98
PubMed 2388921
Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis
Br J Cancer, 62 (4), 585-90
DOI 10.1038/bjc.1990.334, PubMed 1977466
Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy
Br J Cancer, 61 (4), 639-43
DOI 10.1038/bjc.1990.142, PubMed 2109999
PstI polymorphism at the human P1450 gene on chromosome 15
Nucleic Acids Res, 18 (10), 3114
DOI 10.1093/nar/18.10.3114, PubMed 1971943
Spinal muscular atrophy type I combined with atrial septal defect in three sibs
Clin Genet, 38 (2), 81-3
DOI 10.1111/j.1399-0004.1990.tb03553.x, PubMed 2208769
Ha-ras-1 alleles in Norwegian lung cancer patients
Hum Genet, 86 (1), 40-4
DOI 10.1007/BF00205169, PubMed 1979305
Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients
Br J Cancer, 61 (6), 809-12
DOI 10.1038/bjc.1990.182, PubMed 1973618
Publications 1989
[Gene technology in clinical medicine--technics and tools]
Tidsskr Nor Laegeforen, 109 (28), 2882-7
PubMed 2815027
[Genetic variation and genetic diseases]
Tidsskr Nor Laegeforen, 109 (29), 3003-9
PubMed 2588229
[Gene technology in the prevention of cancer]
Tidsskr Nor Laegeforen, 109 (33), 3430-4
PubMed 2609305
Loss of 3p or 11p alleles is associated with testicular cancer tumors
Genomics, 5 (1), 134-8
DOI 10.1016/0888-7543(89)90097-9, PubMed 2767683
Publications 1988
Prenatal diagnosis in a female carrying a deletion close to the Duchenne locus
Prenat Diagn, 8 (1), 67-72
DOI 10.1002/pd.1970080110, PubMed 3422736
Detection of base mutations in genomic DNA using denaturing gradient gel electrophoresis (DGGE) followed by transfer and hybridization with gene-specific probes
Mutat Res, 202 (1), 77-83
DOI 10.1016/0027-5107(88)90166-2, PubMed 2903443
Linkage disequilibrium analyses and restriction mapping of four RFLPs at the pro alpha 2(I) collagen locus: lack of correlation between linkage disequilibrium and physical distance
Hum Genet, 78 (3), 216-21
DOI 10.1007/BF00291664, PubMed 2894343
Publications 1987
Evidence for a sperm mutation resulting in Duchenne muscular dystrophy
Clin Genet, 32 (3), 187-91
DOI 10.1111/j.1399-0004.1987.tb03352.x, PubMed 2887319
Prenatal diagnosis of glycerol-kinase deficiency associated with a DNA deletion on the short arm of the X-chromosome
Clin Genet, 32 (4), 254-9
DOI 10.1111/j.1399-0004.1987.tb03309.x, PubMed 2890456
Effect of haptoglobin subtypes on serum lipid levels
Hum Hered, 37 (3), 150-6
DOI 10.1159/000153693, PubMed 3583295
Mutagenicity testing of human milk from smokers and non-smokers in the Salmonella/microsome test
Life Sci, 41 (21), 2389-96
DOI 10.1016/0024-3205(87)90663-1, PubMed 3316890
[Fabry's disease detected by renal biopsy]
Tidsskr Nor Laegeforen, 107 (9), 848, 873
PubMed 3109070
Publications 1986
RFLPs in collagen loci and disease
Ann Clin Res, 18 (5-6), 258-63
PubMed 2882728
The molecular weight of sodium hyaluronate in amniotic fluid
Biochem Med Metab Biol, 35 (2), 219-26
DOI 10.1016/0885-4505(86)90077-0, PubMed 3707753
Marfan syndrome: exclusion of genetic linkage to the COL1A2 gene
Clin Genet, 30 (5), 428-32
PubMed 2879657
Publications 1985
DNA polymorphisms in collagen genes: potential use in the study of disease
Prog Clin Biol Res, 177, 37-51
PubMed 2989837
DNA polymorphism of the RC8 probe on the X-chromosome. Identification of a new DNA variant with the TaqI enzyme
Clin Genet, 27 (4), 411-3
DOI 10.1111/j.1399-0004.1985.tb02285.x, PubMed 2986884
Deficiency of fumarylacetoacetase without hereditary tyrosinemia
Clin Genet, 27 (6), 550-4
DOI 10.1111/j.1399-0004.1985.tb02039.x, PubMed 4017276
Prenatal diagnosis of hereditary tyrosinemia by determination of fumarylacetoacetase in cultured amniotic fluid cells
Pediatr Res, 19 (4), 334-7
DOI 10.1203/00006450-198519040-00002, PubMed 4000758
Increased frequency of the apolipoprotein E-4 isoform in male subjects with multifactorial hypercholesterolemia
Clin Genet, 27 (5), 458-62
DOI 10.1111/j.1399-0004.1985.tb00231.x, PubMed 4006269
Maximal low density lipoprotein receptor activity and the effect of lipid lowering diet on total serum cholesterol
Clin Genet, 27 (6), 543-9
DOI 10.1111/j.1399-0004.1985.tb02038.x, PubMed 4017275
Publications 1984
The gene for apolipoprotein C-II is closely linked to the gene for apolipo-protein E on chromosome 19
Clin Genet, 26 (5), 389-96
PubMed 6094053
Increase in the ratio of serum levels of apolipoproteins A-I and A-II during prolonged physical strain and calorie deficiency
Eur J Appl Physiol Occup Physiol, 53 (1), 21-4
DOI 10.1007/BF00964684, PubMed 6439559
A comparative study of serum amyloid a protein (SAA) from mink and man
Comp Biochem Physiol B, 78 (2), 401-6
DOI 10.1016/0305-0491(84)90049-x, PubMed 6467904
Molecular heterogeneity in the mild autosomal dominant forms of osteogenesis imperfecta
Am J Hum Genet, 36 (6), 1172-9
PubMed 6097110
Transport and distribution of homocarnosine after intracerebroventricular and intravenous injection in the rat
Neurochem Res, 9 (5), 637-48
DOI 10.1007/BF00964510, PubMed 6472567
Publications 1982
Serum reserve cholesterol binding capacity (SRCBC) in familial hypercholesterolemia
Clin Genet, 21 (6), 362-5
DOI 10.1111/j.1399-0004.1982.tb01388.x, PubMed 6813000
Prenatal diagnosis of homocystinuria
Lancet, 2 (8303), 875
DOI 10.1016/s0140-6736(82)90835-2, PubMed 6126732
Publications 1981
Apparent influence of marker genotypes on variation in serum cholesterol in monozygotic twins
Clin Genet, 19 (1), 67-70
DOI 10.1111/j.1399-0004.1981.tb00670.x, PubMed 6936104
Serum reserve cholesterol binding capacity (SRCBC): the relative importance of different lipoprotein classes
Artery, 9 (2), 96-119
PubMed 6794547
The apoE polymorphism studied by two-dimensional, high-resolution gel electrophoresis of serum
Clin Genet, 20 (6), 438-48
DOI 10.1111/j.1399-0004.1981.tb01055.x, PubMed 7199983
The effect of Gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC)
Artery, 9 (1), 77-86
PubMed 7018466
A twin study of aryl hydrocarbon hydroxylase (AHH) inducibility in cultured lymphocytes
Clin Genet, 19 (4), 281-9
DOI 10.1111/j.1399-0004.1981.tb00710.x, PubMed 6944164
Low density lipoprotein receptor activity in cultured fibroblasts from subjects with or without ischemic heart disease (in the absence of familial hypercholesterolemia)
Clin Genet, 20 (5), 337-46
DOI 10.1111/j.1399-0004.1981.tb01045.x, PubMed 6277536
Publications 1980
Presence of "free" apoA-I in serum: implications for immunological quantification of HDL and its apoproteins
Artery, 7 (2), 139-60
PubMed 7425861
Effect of gemfibrozil on serum lipid levels
Artery, 7 (3), 224-31
PubMed 7008748
Degradation of amyloid-related serum protein SAA by a component present in rabbit and human serum
Scand J Immunol, 11 (6), 643-8
DOI 10.1111/j.1365-3083.1980.tb00033.x, PubMed 6777866
Publications 1979
Effect of smoking on serum levels of HDL apoproteins
Atherosclerosis, 34 (3), 339-43
DOI 10.1016/s0021-9150(79)80011-8, PubMed 229876
Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males
Clin Genet, 16 (5), 347-52
DOI 10.1111/j.1399-0004.1979.tb01014.x, PubMed 230000
High-density lipoprotein as carrier for amyloid-related protein SAA in rabbit serum
Scand J Immunol, 10 (1), 39-45
DOI 10.1111/j.1365-3083.1979.tb01332.x, PubMed 224449
Publications 1978
The distribution of the inherited Hl 1 and R 67 antigens on rabbit serum high density lipoprotein (HDL) particles
J Immunogenet, 5 (1), 13-23
DOI 10.1111/j.1744-313x.1978.tb00626.x, PubMed 205613
Biochemical and genetic studies of the high density lipoprotein (HDL) polymorphisms in rabbit serum
Institute of Medical Genetics, University of Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 950796719
Purification and partial characterization of the apoA-I of rabbit high density lipoprotein
J Immunogenet, 5 (1), 5-12
DOI 10.1111/j.1744-313x.1978.tb00625.x, PubMed 205614
Partial purification and characterization of the inherited Hl 1 and R 67 antigens of rabbit serum high density lipoprotein
J Immunogenet, 5 (2), 71-86
DOI 10.1111/j.1744-313x.1978.tb00633.x, PubMed 207781
Publications 1977
High densitiy lipoprotein (HDL) polymorphisms in rabbit: production of antibody to rabbit allotype (R 67) in sheep
J Immunogenet, 4 (3), 149-58
PubMed 197172
A linkage study of rabbit serum high density lipoprotein (HDL) allotypes
J Immunogenet, 4 (2), 81-95
DOI 10.1111/j.1744-313x.1977.tb00618.x, PubMed 194985
Publications 1976
Serum-high-density-lipoprotein and atherosclerotic heart-disease
Lancet, 1 (7958), 499-501
DOI 10.1016/s0140-6736(76)90291-9, PubMed 55778
Letter: Serum-H.D.L. in a therosclerotic heart-disease
Lancet, 2 (7975), 40-1
DOI 10.1016/s0140-6736(76)92991-3, PubMed 59096
High density lipoprotein (HDL) polymorphisms in rabbit. II. A study of the inherited Hl 1 and R 67 antigens in relation to HDL polypeptides
J Immunogenet, 3 (2), 83-9
PubMed 58949
High density lipoprotein (HDL) polymorphisms in rabbit. III. Quantitative determination of HDL and the inherited Hl 1 and R 67 antigens
J Immunogenet, 3 (2), 91-103
PubMed 58950
High density lipoprotein (HDL) polymorphisms in rabbit. I. A comparative study of rabbit and human serum high density lipoprotein
J Immunogenet, 3 (2), 73-81
PubMed 180184
Letter: Prenatal metachromatic leukodystrophy
Helv Paediatr Acta, 30 (6), 553
PubMed 1270328
Publications 1973
Metachromatic leukodystrophy. II. Direct determination of arylsulphatase A activity in amniotic fluid
Clin Genet, 4 (5), 442-6
PubMed 4751314
Metachromatic leukodystrophy. I. Prenatal detection of arylsulphatase A deficiency
Clin Genet, 4 (3), 256-9
PubMed 4765208
Publications 1972
Preliminary assignment of the inherited Hl 1 antigen to the apoA-I polypeptide of rabbit high density lipoprotein
FEBS Lett, 28 (2), 153-155
DOI 10.1016/0014-5793(72)80699-9, PubMed 11946845